Calcineurin	B-protein
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
consists	O
of	O
several	O
independent	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
(	I-DNA
TcR	I-DNA
)	I-DNA
responsive	I-DNA
elements	I-DNA
.	O

The	O
induction	O
of	O
promoters	B-DNA
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O

Calcineurin	B-protein
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
is	O
the	O
FK-506	O
-and	O
CsA-sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
partially	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
activate	O
the	O
IL-2	B-DNA
promoter	I-DNA
elements	I-DNA
IL-2A	B-DNA
(	O
which	O
binds	O
the	O
factors	O
OAP	B-protein
and	O
Oct-1	B-protein
)	O
and	O
IL-2E	B-DNA
(	O
which	O
binds	O
NF-AT	B-protein
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
stimulate	O
an	O
NF-kappa	B-protein
B	I-protein
-dependent	O
element	O
.	O

Calcineurin	B-protein
stimulates	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
by	O
enhancing	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	B-protein
phosphatase	I-protein
can	O
inactivate	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism-based	O
toxicities	O
associated	O
with	O
FK-506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	B-protein
-dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.13	NULL
no.4	NULL
pp.861-870	NULL
,	NULL
1994	NULL
Calcineurin	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
IxB/MAD3	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-xB	NULL
Betsy	NULL
Frantz	NULL
``	NULL
,	NULL
Eric	NULL
C.Nordby	NULL
'	NULL
,	NULL
Gary	NULL
Bren	NULL
,	NULL
Nora	NULL
Steffan	NULL
``	NULL
,	NULL
Carlos	NULL
V.Paya2	NULL
,	NULL
Randall	NULL
L.Kincaid®	NULL
,	NULL
Michael	NULL
J.Tocci	NULL
'	NULL
,	NULL
Stephen	NULL
J.O'Keefe	NULL
'	NULL
and	NULL
Edward	NULL
A.O'Neill	NULL
'	NULL
*	NULL
'Department	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
Merck	NULL
Research	NULL
Laboratories	NULL
,	NULL
Rahway	NULL
,	NULL
NJ	NULL
07065	NULL
,	NULL
@	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Mayo	NULL
Clinic	NULL
,	NULL
Rochester	NULL
,	NULL
MN	NULL
55905	NULL
and	NULL
Section	NULL
on	NULL
Immunology	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Neurobiology	NULL
,	NULL
National	NULL
Institute	NULL
on	NULL
Alcohol	NULL
Abuse	NULL
and	NULL
Alcoholism	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
,	NULL
USA	NULL
4Corresponding	NULL
author	NULL
Communicated	NULL
by	NULL
A.R	NULL
.	NULL

Williamson	NULL
The	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
consists	NULL
of	NULL
several	NULL
independent	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TcR	NULL
)	NULL
responsive	NULL
elements	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
promoters	NULL
dependent	NULL
on	NULL
these	NULL
elements	NULL
is	NULL
inhibitable	NULL
by	NULL
the	NULL
immunosuppressants	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
tacrolimus	NULL
(	NULL
FK-506	NULL
)	NULL
.	NULL

Calcineurin	NULL
,	NULL
a	NULL
Ca*+*/calmodulin-dependent	NULL
protein	NULL
phosphatase	NULL
,	NULL
is	NULL
the	NULL
FK-506-	NULL
and	NULL
CsA-sensitive	NULL
enzyme	NULL
required	NULL
for	NULL
TcR	NULL
mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

We	NULL
report	NULL
that	NULL
a	NULL
constitutively	NULL
active	NULL
form	NULL
of	NULL
calcineurin	NULL
partially	NULL
substitutes	NULL
for	NULL
the	NULL
Ca®+*	NULL
co-stimulus	NULL
required	NULL
to	NULL
activate	NULL
the	NULL
IL-2	NULL
promoter	NULL
elements	NULL
IL-2A	NULL
(	NULL
which	NULL
binds	NULL
the	NULL
factors	NULL
OAP	NULL
and	NULL
Oct-1	NULL
)	NULL
and	NULL
IL-2E	NULL
(	NULL
which	NULL
binds	NULL
NF-AT	NULL
)	NULL
,	NULL
and	NULL
completely	NULL
substitutes	NULL
for	NULL
the	NULL
co-stimulus	NULL
required	NULL
to	NULL
stimulate	NULL
an	NULL
NF-xB-dependent	NULL
element	NULL
.	NULL

Calcineurin	NULL
stimulates	NULL
the	NULL
NF-xB	NULL
element	NULL
by	NULL
enhancing	NULL
inactivation	NULL
of	NULL
IxB/MAD3	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-xB	NULL
,	NULL
thereby	NULL
increasing	NULL
the	NULL
amount	NULL
of	NULL
nuclear	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

These	NULL
data	NULL
provide	NULL
the	NULL
first	NULL
demonstration	NULL
in	NULL
vivo	NULL
that	NULL
activation	NULL
of	NULL
a	NULL
protein	NULL
phosphatase	NULL
can	NULL
inactivate	NULL
IxB	NULL
,	NULL
and	NULL
suggest	NULL
one	NULL
possible	NULL
explanation	NULL
for	NULL
mechanism-based	NULL
toxicities	NULL
associated	NULL
with	NULL
FK-506	NULL
and	NULL
CsA	NULL
by	NULL
demonstrating	NULL
that	NULL
these	NULL
drugs	NULL
can	NULL
inhibit	NULL
the	NULL
calcineurin-dependent	NULL
activation	NULL
of	NULL
a	NULL
virtually	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
calcineurin/cyclosporin	NULL
A/interleukin-2/tacro-limus/transcription	NULL
Introduction	NULL
Intracellular	NULL
Ca	NULL
*	NULL
release	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
many	NULL
fundamental	NULL
cellular	NULL
activities	NULL
(	NULL
Berridge	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

One	NULL
series	NULL
of	NULL
events	NULL
in	NULL
which	NULL
the	NULL
importance	NULL
of	NULL
Ca	NULL
*	NULL
release	NULL
has	NULL
been	NULL
very	NULL
well	NULL
documented	NULL
is	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
antigen	NULL
stimulation	NULL
.	NULL

As	NULL
with	NULL
numerous	NULL
other	NULL
receptor-initiated	NULL
cellular	NULL
processes	NULL
(	NULL
Berridge	NULL
,	NULL
1993	NULL
)	NULL
,	NULL
interaction	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TcR	NULL
)	NULL
with	NULL
an	NULL
appropriately	NULL
presented	NULL
antigen	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
phospholipase	NULL
C	NULL
(	NULL
PLC	NULL
)	NULL
which	NULL
hydrolyzes	NULL
phosphatidylinositol	NULL
4,5-bisphos-phate	NULL
(	NULL
PIP	NULL
;	NULL
)	NULL
to	NULL
inositol	NULL
1,4,5-trisphosphate	NULL
(	NULL
IP	NULL
;	NULL
)	NULL
and	NULL
1,2-sn-diacylglycerol	NULL
(	NULL
DAG	NULL
)	NULL
.	NULL

IP	NULL
;	NULL
binds	NULL
an	NULL
intracellular	NULL
receptor	NULL
(	NULL
IP	NULL
;	NULL
R	NULL
)	NULL
causing	NULL
stored	NULL
Ca*+	NULL
to	NULL
be	NULL
released	NULL
,	NULL
while	NULL
DAG	NULL
causes	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
Ca**	NULL
in	NULL
TcR	NULL
signal	NULL
transduction	NULL
can	NULL
be	NULL
demonstrated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
removal	NULL
of	NULL
extracellular	NULL
Ca	NULL
?	NULL

*	NULL
can	NULL
block	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
Alford	NULL
,	NULL
1970	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
same	NULL
cellular	NULL
events	NULL
initiated	NULL
by	NULL
receptor	NULL
mediated	NULL
activation	NULL
of	NULL
PLC	NULL
can	NULL
also	NULL
be	NULL
initiated	NULL
by	NULL
treatment	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
a	NULL
Ca	NULL
+	NULL
ionophore	NULL
,	NULL
raising	NULL
intracellular	NULL
Ca	NULL
+	NULL
levels	NULL
,	NULL
and	NULL
a	NULL
phorbol	NULL
ester	NULL
,	NULL
presumably	NULL
activating	NULL
PKC	NULL
(	NULL
Truneh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

While	NULL
the	NULL
importance	NULL
of	NULL
Ca+*	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
has	NULL
been	NULL
appreciated	NULL
for	NULL
many	NULL
years	NULL
,	NULL
an	NULL
immediate	NULL
target	NULL
of	NULL
free	NULL
Ca°+	NULL
has	NULL
only	NULL
recently	NULL
been	NULL
documented	NULL
.	NULL

Calcineurin	NULL
,	NULL
a	NULL
Ca**/calmodulin-activated	NULL
phosphatase	NULL
,	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
an	NULL
important	NULL
component	NULL
of	NULL
the	NULL
TcR	NULL
signal	NULL
transduction	NULL
network	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
most	NULL
direct	NULL
evidence	NULL
supporting	NULL
this	NULL
conclusion	NULL
was	NULL
obtained	NULL
in	NULL
a	NULL
model	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
events	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
activity	NULL
in	NULL
the	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
Jurkat	NULL
.	NULL

This	NULL
model	NULL
recapitulates	NULL
two	NULL
important	NULL
characteristics	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

First	NULL
,	NULL
the	NULL
Ca	NULL
@	NULL
+*	NULL
ionophore	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
the	NULL
phorbol	NULL
ester	NULL
,	NULL
phorbol	NULL
myristyl	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
act	NULL
in	NULL
synergy	NULL
to	NULL
induce	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
both	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
Jurkat	NULL
cells	NULL
(	NULL
Manger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
immunosuppressant	NULL
molecules	NULL
tacrolimus	NULL
(	NULL
FK-506	NULL
)	NULL
and	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
which	NULL
prevent	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
inhibiting	NULL
the	NULL
antigen-dependent	NULL
induction	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
also	NULL
inhibit	NULL
the	NULL
ionomycin-and	NULL
PMA-induction	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
both	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
Jurkat	NULL
cells	NULL
(	NULL
Sigal	NULL
and	NULL
Dumont	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
the	NULL
Jurkat	NULL
model	NULL
system	NULL
a	NULL
deletion	NULL
mutant	NULL
of	NULL
calcineurin	NULL
providing	NULL
Ca**-independent	NULL
,	NULL
constitutive	NULL
phosphatase	NULL
activity	NULL
can	NULL
substitute	NULL
for	NULL
ionophore	NULL
,	NULL
acting	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
induce	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
the	NULL
Ca*+*-independent	NULL
mutant	NULL
calcineurin	NULL
is	NULL
sensitive	NULL
to	NULL
FK-506	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
either	NULL
a	NULL
wild-type	NULL
or	NULL
mutant	NULL
calcineurin	NULL
causes	NULL
Jurkat	NULL
cells	NULL
to	NULL
be	NULL
more	NULL
resistant	NULL
to	NULL
the	NULL
immunosuppressant	NULL
drugs	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
O'Keefe	NULL
eral	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
calcineurin	NULL
is	NULL
known	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
Kincaid	NULL
eral	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
and	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
is	NULL
inhibited	NULL
by	NULL
immunosuppressive	NULL
analogs	NULL
of	NULL
both	NULL
FK-506	NULL
and	NULL
CsA	NULL
and	NULL
resistant	NULL
to	NULL
non-immuno-suppressive	NULL
analogs	NULL
(	NULL
Fruman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

No	NULL
other	NULL
enzyme	NULL
with	NULL
these	NULL
characteristics	NULL
has	NULL
been	NULL
identified	NULL
,	NULL
thus	NULL
calcineurin	NULL
is	NULL
now	NULL
considered	NULL
to	NULL
be	NULL
an	NULL
essential	NULL
mediator	NULL
of	NULL
one	NULL
signal	NULL
through	NULL
which	NULL
antigen	NULL
stimulation	NULL
of	NULL
the	NULL
TcR	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
calcineurin	NULL
participates	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
we	NULL
examined	NULL
its	NULL
role	NULL
in	NULL
events	NULL
leading	NULL
to	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
specific	NULL
enhancer-binding	NULL
transcription	NULL
factors	NULL
regulates	NULL
initiation	NULL
of	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Riegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

DNA	NULL
sequences	NULL
recognized	NULL
by	NULL
these	NULL
factors	NULL
861	NULL
B.Frantz	NULL
et	NULL
al	NULL
.	NULL

are	NULL
found	NULL
within	NULL
the	NULL
300	NULL
base	NULL
pairs	NULL
preceding	NULL
the	NULL
IL-2	NULL
gene	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

There	NULL
are	NULL
minimally	NULL
five	NULL
factors	NULL
,	NULL
uniquely	NULL
defined	NULL
by	NULL
nucleotide	NULL
sequence	NULL
recognition	NULL
,	NULL
essential	NULL
for	NULL
(	NULL
ionomycin	NULL
+	NULL
PMA	NULL
)	NULL
-induced	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
:	NULL
NF-AT	NULL
,	NULL
which	NULL
binds	NULL
the	NULL
IL-2E	NULL
element	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
,	NULL
NF-xB	NULL
,	NULL
which	NULL
binds	NULL
the	NULL
IL-2C	NULL
element	NULL
(	NULL
Baumann	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Briegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Hoyos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Shibuya	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
AP-1	NULL
,	NULL
which	NULL
recognizes	NULL
a	NULL
sequence	NULL
within	NULL
the	NULL
IL-2B	NULL
element	NULL
(	NULL
Jain	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992a	NULL
,	NULL
b	NULL
;	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
and	NULL
OAP	NULL
(	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
Oct-1	NULL
(	NULL
Kamps	NULL
etal	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
which	NULL
function	NULL
together	NULL
,	NULL
each	NULL
recognizing	NULL
an	NULL
independent	NULL
sequence	NULL
within	NULL
the	NULL
IL-2A	NULL
element	NULL
(	NULL
Durand	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
each	NULL
of	NULL
these	NULL
factors	NULL
except	NULL
Oct-1	NULL
is	NULL
induced	NULL
to	NULL
varying	NULL
degrees	NULL
by	NULL
ionomycin	NULL
and	NULL
PMA	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
.	NULL

Similarly	NULL
,	NULL
when	NULL
artificial	NULL
enhancers	NULL
consisting	NULL
of	NULL
multiple	NULL
copies	NULL
of	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
these	NULL
factors	NULL
are	NULL
linked	NULL
to	NULL
otherwise	NULL
inactive	NULL
enhancerless	NULL
promoters	NULL
different	NULL
levels	NULL
of	NULL
transcription	NULL
activity	NULL
can	NULL
be	NULL
observed	NULL
in	NULL
response	NULL
to	NULL
ionomycin	NULL
and/or	NULL
PMA	NULL
.	NULL

When	NULL
the	NULL
responses	NULL
of	NULL
each	NULL
artificial	NULL
enhancer	NULL
to	NULL
ionomycin	NULL
,	NULL
PMA	NULL
,	NULL
and	NULL
FK-506	NULL
or	NULL
CsA	NULL
,	NULL
are	NULL
compared	NULL
,	NULL
they	NULL
fall	NULL
into	NULL
three	NULL
classes	NULL
.	NULL

(	NULL
i	NULL
)	NULL
NF-AT-	NULL
and	NULL
OAP/Oct-dependent	NULL
enhancers	NULL
are	NULL
slightly	NULL
responsive	NULL
to	NULL
ionomycin	NULL
,	NULL
unresponsive	NULL
to	NULL
PMA	NULL
,	NULL
but	NULL
very	NULL
responsive	NULL
to	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ionomycin	NULL
.	NULL

Their	NULL
activation	NULL
is	NULL
completely	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
Mattila	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
An	NULL
NF-xB-dependent	NULL
enhancer	NULL
is	NULL
responsive	NULL
to	NULL
PMA	NULL
,	NULL
unresponsive	NULL
to	NULL
ionomycin	NULL
,	NULL
but	NULL
very	NULL
responsive	NULL
to	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
.	NULL

The	NULL
ionomycin-dependent	NULL
but	NULL
not	NULL
the	NULL
PMA-dependent	NULL
activity	NULL
of	NULL
the	NULL
NF-xB	NULL
enhancer	NULL
is	NULL
sensitive	NULL
to	NULL
the	NULL
immunosuppressants	NULL
(	NULL
Mattila	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
An	NULL
AP-1-dependent	NULL
enhancer	NULL
is	NULL
very	NULL
responsive	NULL
to	NULL
PMA	NULL
and	NULL
does	NULL
not	NULL
respond	NULL
to	NULL
ionomycin	NULL
alone	NULL
.	NULL

The	NULL
PMA-dependent	NULL
activation	NULL
of	NULL
AP-1	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
ionomycin	NULL
and	NULL
FK-506	NULL
prevents	NULL
this	NULL
inhibition	NULL
(	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

When	NULL
these	NULL
data	NULL
are	NULL
considered	NULL
within	NULL
the	NULL
context	NULL
of	NULL
the	NULL
preceding	NULL
discussion	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
calcineurin	NULL
would	NULL
have	NULL
a	NULL
role	NULL
in	NULL
activating	NULL
the	NULL
factors	NULL
defined	NULL
as	NULL
NF-AT	NULL
,	NULL
OAP/Oct	NULL
and	NULL
NF-xB	NULL
,	NULL
and	NULL
perhaps	NULL
has	NULL
a	NULL
role	NULL
in	NULL
suppressing	NULL
the	NULL
activity	NULL
of	NULL
AP-1	NULL
.	NULL

If	NULL
so	NULL
,	NULL
any	NULL
of	NULL
these	NULL
factors	NULL
might	NULL
be	NULL
a	NULL
substrate	NULL
for	NULL
calcineurin	NULL
or	NULL
,	NULL
perhaps	NULL
,	NULL
a	NULL
target	NULL
several	NULL
steps	NULL
removed	NULL
from	NULL
calcineurin	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
role	NULL
of	NULL
calcineurin	NULL
in	NULL
activating	NULL
these	NULL
transcription	NULL
factors	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
Ca*+*-independent	NULL
calcineurin	NULL
mutant	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
artificial	NULL
enhancers	NULL
described	NULL
above	NULL
.	NULL

The	NULL
data	NULL
we	NULL
present	NULL
suggest	NULL
that	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
Ca*+	NULL
affects	NULL
all	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
tested	NULL
through	NULL
calcineurin	NULL
and	NULL
,	NULL
in	NULL
addition	NULL
,	NULL
Ca*	NULL
affects	NULL
all	NULL
but	NULL
the	NULL
NF-xB	NULL
transcription	NULL
factor	NULL
through	NULL
another	NULL
non-calcineurin	NULL
Ca*+*-responsive	NULL
activity	NULL
.	NULL

To	NULL
discern	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
calcineurin	NULL
can	NULL
activate	NULL
a	NULL
transcription	NULL
factor	NULL
we	NULL
determined	NULL
how	NULL
calcineurin	NULL
participates	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
xB-enhancer-dependent	NULL
promoter	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
through	NULL
calcineurin	NULL
,	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
IxB/MAD3	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-xB	NULL
,	NULL
thus	NULL
increasing	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
resulting	NULL
in	NULL
increased	NULL
NF-xB-dependent	NULL
enhancer	NULL
activity	NULL
.	NULL

Results	NULL
Calcineurin	NULL
affects	NULL
the	NULL
activity	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
Transient	NULL
expression	NULL
of	NULL
ACaM-AI	NULL
,	NULL
a	NULL
Ca*+*-independent	NULL
calcineurin	NULL
catalytic	NULL
subunit	NULL
,	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
partially	NULL
862	NULL
SS	NULL
+	NULL
I	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

A	NULL
graphic	NULL
representation	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
(	NULL
CAT	NULL
)	NULL
activity	NULL
produced	NULL
by	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
.	NULL

All	NULL
transfections	NULL
included	NULL
the	NULL
indicated	NULL
promoter-reporter	NULL
plasmid	NULL
,	NULL
encoding	NULL
CAT	NULL
,	NULL
either	NULL
a	NULL
control	NULL
expression	NULL
vector	NULL
pSRae	NULL
(	NULL
-	NULL
)	NULL
or	NULL
the	NULL
expression	NULL
vector	NULL
,	NULL
pSRa4ACaM-AI	NULL
,	NULL
encoding	NULL
a	NULL
constitutively	NULL
active	NULL
calcineurin	NULL
catalytic	NULL
subunit	NULL
(	NULL
+	NULL
)	NULL
,	NULL
and	NULL
a	NULL
control	NULL
reporter	NULL
,	NULL
pCMV.Gal	NULL
,	NULL
which	NULL
encodes	NULL
-galactosidase	NULL
.	NULL

The	NULL
promoter-reporter	NULL
constructs	NULL
each	NULL
consist	NULL
of	NULL
an	NULL
artificial	NULL
enhancer	NULL
fused	NULL
to	NULL
an	NULL
enhancerless	NULL
gamma-fibrinogen	NULL
Spl/TATA	NULL
element	NULL
controlling	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

The	NULL
artificial	NULL
enhancers	NULL
are	NULL
(	NULL
A	NULL
)	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
IL-2A	NULL
element	NULL
(	NULL
pTAn.A.4	NULL
)	NULL
,	NULL
(	NULL
B	NULL
)	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
IL-2E	NULL
element	NULL
(	NULL
pTAn.E.3	NULL
)	NULL
,	NULL
(	NULL
C	NULL
)	NULL
six	NULL
copies	NULL
of	NULL
an	NULL
NF-xB	NULL
binding	NULL
site	NULL
(	NULL
pTAn.xB.6	NULL
)	NULL
or	NULL
(	NULL
D	NULL
)	NULL
three	NULL
copies	NULL
of	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
pDAn.AP-1.3	NULL
)	NULL
.	NULL

When	NULL
the	NULL
enhancerless	NULL
promoter	NULL
(	NULL
pDAn.yf.CAT	NULL
)	NULL
was	NULL
tested	NULL
in	NULL
this	NULL
experiment	NULL
no	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
untreated	NULL
(	NULL
MW	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
MA	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
M	NULL
)	NULL
,	NULL
PMA	NULL
+ionomycin	NULL
(	NULL
@	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
+	NULL
ionomycin+FK-506	NULL
(	NULL
0	NULL
)	NULL
.	NULL

For	NULL
each	NULL
promoter	NULL
the	NULL
CAT	NULL
activity	NULL
induced	NULL
by	NULL
the	NULL
indicated	NULL
treatment	NULL
is	NULL
shown	NULL
relative	NULL
to	NULL
the	NULL
(	NULL
PMA	NULL
+	NULL
ionomycin	NULL
)	NULL
-induced	NULL
CAT	NULL
activity	NULL
of	NULL
the	NULL
pSRa	NULL
control	NULL
,	NULL
which	NULL
was	NULL
set	NULL
to	NULL
100	NULL
.	NULL

In	NULL
each	NULL
experiment	NULL
the	NULL
amount	NULL
of	NULL
CAT	NULL
activity	NULL
produced	NULL
was	NULL
normalized	NULL
to	NULL
both	NULL
the	NULL
protein	NULL
concentration	NULL
in	NULL
the	NULL
extract	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
-galactosidase	NULL
activity	NULL
in	NULL
extracts	NULL
of	NULL
PMA-treated	NULL
cells	NULL
from	NULL
the	NULL
same	NULL
transfection	NULL
.	NULL

Each	NULL
data	NULL
set	NULL
is	NULL
the	NULL
average	NULL
of	NULL
three	NULL
or	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

substitutes	NULL
for	NULL
the	NULL
increased	NULL
concentration	NULL
of	NULL
intracellular	NULL
Ca	NULL
``	NULL
+	NULL
required	NULL
as	NULL
a	NULL
co-inducer	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
transcription	NULL
factors	NULL
activated	NULL
by	NULL
calcineurin	NULL
we	NULL
compared	NULL
the	NULL
activities	NULL
of	NULL
promoters	NULL
dependent	NULL
on	NULL
multimers	NULL
of	NULL
individual	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
ACaM-AI	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

Three	NULL
of	NULL
the	NULL
elements	NULL
tested	NULL
,	NULL
IL-2	NULL
(	NULL
recognized	NULL
by	NULL
Oct-1	NULL
and	NULL
OAP	NULL
)	NULL
,	NULL
IL-2E	NULL
[	NULL
recognized	NULL
by	NULL
NF-AT	NULL
and	NULL
Ets	NULL
factors	NULL
(	NULL
Thompson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
]	NULL
and	NULL
NF-xB	NULL
,	NULL
were	NULL
induced	NULL
by	NULL
a	NULL
synergistic	NULL
interaction	NULL
between	NULL
either	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
a	NULL
Ca*+	NULL
ionophore	NULL
)	NULL
or	NULL
PMA	NULL
and	NULL
ACaM-AI	NULL
.	NULL

In	NULL
each	NULL
case	NULL
the	NULL
effect	NULL
of	NULL
either	NULL
ionomycin	NULL
or	NULL
ACaM-AI	NULL
was	NULL
sensitive	NULL
to	NULL
FK-506	NULL
.	NULL

ACaM-AlI	NULL
substituted	NULL
for	NULL
ionomycin	NULL
co-induction	NULL
of	NULL
IL-2	NULL
but	NULL
the	NULL
combination	NULL
of	NULL
ACaM-AI	NULL
and	NULL
ionomycin	NULL
with	NULL
PMA	NULL
was	NULL
consistently	NULL
more	NULL
effective	NULL
at	NULL
activating	NULL
this	NULL
promoter	NULL
than	NULL
either	NULL
separately	NULL
with	NULL
PMA	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

ACaM-AI	NULL
only	NULL
partially	NULL
substituted	NULL
for	NULL
ionomycin	NULL
co-induction	NULL
of	NULL
IL-2E	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
,	NULL
and	NULL
in	NULL
contrast	NULL
to	NULL
both	NULL
IL-2A	NULL
and	NULL
NF-xB	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
ACaM-AI	NULL
does	NULL
not	NULL
increase	NULL
A	NULL
>	NULL
bed	NULL
ind	NULL
be	NULL
bud	NULL
bad	NULL
bod	NULL
bed	NULL
bd	NULL
bub	NULL
bud	NULL
be	NULL
but	NULL
-	NULL
bud	NULL
B	NULL
(	NULL
D	NULL
l	NULL
but	NULL
tnd	NULL
but	NULL
bns	NULL
-	NULL
buf	NULL
tout	NULL
bud	NULL
E	NULL
ind	NULL
ind	NULL
ind	NULL
bad	NULL
bd	NULL
bad	NULL
ind	NULL
but	NULL
but	NULL
»	NULL
C	NULL
“	NULL
54	NULL
102	NULL
3	NULL
4	NULL
§	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
42	NULL
13	NULL
44	NULL
15	NULL
16	NULL
17	NULL
18	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Gel	NULL
electrophoresis	NULL
DNA	NULL
binding	NULL
assay	NULL
for	NULL
NF-xB	NULL
and	NULL
Oct-1	NULL
in	NULL
extracts	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
all	NULL
panels	NULL
the	NULL
arrow	NULL
indicates	NULL
the	NULL
inducible	NULL
NF-xB	NULL
species	NULL
,	NULL
p	NULL
indicates	NULL
treatment	NULL
with	NULL
PMA	NULL
;	NULL
i	NULL
,	NULL
ionomycin	NULL
and	NULL
5	NULL
,	NULL
FK-506	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
expression	NULL
vector	NULL
,	NULL
pSRa	NULL
(	NULL
lanes	NULL
1-12	NULL
)	NULL
,	NULL
or	NULL
the	NULL
vector	NULL
encoding	NULL
the	NULL
constitutively	NULL
active	NULL
calcineurin	NULL
catalytic	NULL
subunit	NULL
,	NULL
pSRa4ACaM-AI	NULL
(	NULL
lanes	NULL
13-24	NULL
)	NULL
,	NULL
and	NULL
activated	NULL
as	NULL
indicated	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
these	NULL
cells	NULL
and	NULL
NF-xB-specific	NULL
(	NULL
lanes	NULL
1-7	NULL
and	NULL
13-19	NULL
)	NULL
or	NULL
Oct-specific	NULL
(	NULL
lanes	NULL
8-12	NULL
and	NULL
20-24	NULL
)	NULL
DNA	NULL
binding	NULL
activities	NULL
in	NULL
samples	NULL
of	NULL
each	NULL
extract	NULL
were	NULL
measured	NULL
.	NULL

Lanes	NULL
6	NULL
and	NULL
18	NULL
show	NULL
competition	NULL
with	NULL
a	NULL
200-fold	NULL
molar	NULL
excess	NULL
with	NULL
unlabeled	NULL
NF-xB	NULL
DNA	NULL
fragment	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
19	NULL
show	NULL
competition	NULL
with	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
unlabeled	NULL
Oct	NULL
DNA	NULL
fragment	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
cytosolic	NULL
fraction	NULL
from	NULL
uninduced	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
deoxycholate	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
was	NULL
tested	NULL
for	NULL
NF-xB	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
Oct-1	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
DNA	NULL
binding	NULL
activities	NULL
.	NULL

NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
(	NULL
PMA	NULL
+ionomycin	NULL
)	NULL
-treated	NULL
cells	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
3	NULL
for	NULL
comparison	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Nuclear	NULL
extract	NULL
from	NULL
(	NULL
PMA	NULL
+	NULL
ionomycin	NULL
)	NULL
-treated	NULL
cells	NULL
pre-incubated	NULL
with	NULL
0	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
,	NULL
0.5	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
2	NULL
ul	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
of	NULL
anti-p65	NULL
affinity-purified	NULL
antibody	NULL
before	NULL
carrying	NULL
out	NULL
the	NULL
standard	NULL
DNA	NULL
binding	NULL
assay	NULL
.	NULL

NF-xB	NULL
probe	NULL
was	NULL
used	NULL
for	NULL
lanes	NULL
1-3	NULL
and	NULL
Oct	NULL
probe	NULL
for	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Nuclear	NULL
extract	NULL
from	NULL
(	NULL
PMA	NULL
+ionomycin	NULL
)	NULL
-treated	NULL
cells	NULL
pre-incubated	NULL
with	NULL
0	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
,	NULL
0.5	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
2	NULL
ul	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
of	NULL
anti-p50	NULL
antiserum	NULL
before	NULL
carrying	NULL
out	NULL
the	NULL
standard	NULL
DNA	NULL
binding	NULL
assay	NULL
.	NULL

NF-xB	NULL
probe	NULL
was	NULL
used	NULL
for	NULL
lanes	NULL
1-3	NULL
and	NULL
Oct	NULL
probe	NULL
was	NULL
used	NULL
for	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
cells	NULL
treated	NULL
with	NULL
cycloheximide	NULL
(	NULL
10	NULL
pg/ml	NULL
!	NULL
)	NULL

(	NULL
C	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
treated	NULL
for	NULL
3	NULL
h	NULL
as	NULL
indicated	NULL
.	NULL

DNA	NULL
binding	NULL
activity	NULL
in	NULL
each	NULL
extract	NULL
was	NULL
measured	NULL
.	NULL

In	NULL
lanes	NULL
1-9	NULL
NF-xB	NULL
probe	NULL
was	NULL
used	NULL
;	NULL
in	NULL
lanes	NULL
10-18	NULL
Oct	NULL
probe	NULL
was	NULL
used	NULL
.	NULL

the	NULL
activity	NULL
of	NULL
IL-2E	NULL
at	NULL
all	NULL
.	NULL

ACaM-AI	NULL
completely	NULL
substituted	NULL
for	NULL
ionomycin	NULL
co-induction	NULL
of	NULL
NF-xB	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
and	NULL
provides	NULL
significantly	NULL
more	NULL
NF-xB	NULL
activity	NULL
than	NULL
does	NULL
the	NULL
combination	NULL
of	NULL
ionomycin	NULL
and	NULL
PMA	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
only	NULL
event	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
NF-xB	NULL
element	NULL
is	NULL
activation	NULL
of	NULL
calcineurin	NULL
,	NULL
while	NULL
the	NULL
IL-2A	NULL
and	NULL
IL-2E	NULL
elements	NULL
are	NULL
affected	NULL
by	NULL
both	NULL
calcineurin	NULL
activation	NULL
and	NULL
other	NULL
Ca*+*-dependent	NULL
events	NULL
.	NULL

The	NULL
AP-1-dependent	NULL
promoter	NULL
,	NULL
unlike	NULL
the	NULL
other	NULL
three	NULL
elements	NULL
,	NULL
reflects	NULL
no	NULL
positive	NULL
interaction	NULL
between	NULL
calcineurin	NULL
and	NULL
PMA	NULL
.	NULL

Rather	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
this	NULL
enhancer	NULL
is	NULL
stimulated	NULL
by	NULL
FK-506	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
.	NULL

This	NULL
FK-506-dependent	NULL
stimulation	NULL
does	NULL
not	NULL
occur	NULL
in	NULL
PMA-treated	NULL
cells	NULL
that	NULL
have	NULL
not	NULL
been	NULL
exposed	NULL
to	NULL
ionomycin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
suggesting	NULL
that	NULL
induction	NULL
of	NULL
the	NULL
AP-1	NULL
element	NULL
is	NULL
inhibited	NULL
by	NULL
calcineurin	NULL
but	NULL
stimulated	NULL
by	NULL
another	NULL
Ca*+*-dependent	NULL
enzyme	NULL
.	NULL

Calcineurin	NULL
stimulates	NULL
inactivation	NULL
of	NULL
IxB	NULL
Calcineurin	NULL
is	NULL
a	NULL
co-inducer	NULL
of	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
There	NULL
are	NULL
several	NULL
mechanisms	NULL
by	NULL
which	NULL
calcineurin	NULL
might	NULL
act	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
increase	NULL
transcription	NULL
from	NULL
one	NULL
of	NULL
the	NULL
enhancers	NULL
described	NULL
above	NULL
.	NULL

Calcineurin	NULL
could	NULL
stimulate	NULL
(	NULL
i	NULL
)	NULL
PMA-dependent	NULL
induction	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
transcription	NULL
activation	NULL
potential	NULL
of	NULL
a	NULL
PMA-induced	NULL
factor	NULL
,	NULL
or	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
function	NULL
of	NULL
a	NULL
general	NULL
transcription	NULL
factor	NULL
through	NULL
which	NULL
a	NULL
PMA-inducible	NULL
factor	NULL
must	NULL
act	NULL
.	NULL

To	NULL
explore	NULL
these	NULL
alternative	NULL
possibilities	NULL
we	NULL
chose	NULL
to	NULL
focus	NULL
on	NULL
calcineurin	NULL
's	NULL
ability	NULL
to	NULL
stimulate	NULL
transcription	NULL
from	NULL
the	NULL
NF-xB-dependent	NULL
enhancer	NULL
.	NULL

By	NULL
measuring	NULL
the	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
either	NULL
co-stimulated	NULL
with	NULL
ionomycin	NULL
or	NULL
transfected	NULL
with	NULL
ACaM-AI	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
we	NULL
can	NULL
demonstrate	NULL
that	NULL
the	NULL
latter	NULL
two	NULL
explanations	NULL
need	NULL
not	NULL
be	NULL
invoked	NULL
to	NULL
understand	NULL
the	NULL
effect	NULL
of	NULL
calcineurin	NULL
.	NULL

Cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
produce	NULL
4-fold	NULL
more	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
than	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

This	NULL
correlates	NULL
exactly	NULL
with	NULL
the	NULL
fold	NULL
stimulation	NULL
observed	NULL
for	NULL
enhancer	NULL
activation	NULL
under	NULL
similar	NULL
conditions	NULL
.	NULL

Similarly	NULL
,	NULL
ACaM-Al-transfected	NULL
PMA-treated	NULL
cells	NULL
produced	NULL
3-fold	NULL
more	NULL
nuclear	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
than	NULL
control	NULL
PMA	NULL
-treated	NULL
cells	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
14	NULL
)	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
FACS	NULL
quantitation	NULL
of	NULL
transfected	NULL
cells	NULL
using	NULL
B-galactosidase	NULL
produced	NULL
by	NULL
co-transfected	NULL
DNA	NULL
(	NULL
pCMV-Gal	NULL
)	NULL
as	NULL
a	NULL
marker	NULL
indicated	NULL
that	NULL
25	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
express	NULL
the	NULL
gene	NULL
product	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
in	NULL
populations	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
encoding	NULL
ACaM-AI	NULL
the	NULL
observed	NULL
3-fold	NULL
increase	NULL
of	NULL
total	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
within	NULL
the	NULL
whole	NULL
population	NULL
represents	NULL
a	NULL
12-fold	NULL
increase	NULL
within	NULL
cells	NULL
actually	NULL
expressing	NULL
ACaM-AI	NULL
.	NULL

This	NULL
number	NULL
correlates	NULL
very	NULL
well	NULL
with	NULL
the	NULL
observed	NULL
15-fold	NULL
increase	NULL
in	NULL
NF-xB-dependent	NULL
promoter	NULL
activity	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
induced	NULL
by	NULL
expression	NULL
of	NULL
ACaM-AI	NULL
was	NULL
qualitatively	NULL
similar	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
treatment	NULL
with	NULL
ionomycin	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
,	NULL
2	NULL
and	NULL
14	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
no	NULL
Ca*+*-dependent	NULL
event	NULL
other	NULL
than	NULL
calcineurin	NULL
activation	NULL
need	NULL
be	NULL
invoked	NULL
to	NULL
explain	NULL
the	NULL
effects	NULL
of	NULL
ionomycin	NULL
on	NULL
NF-xB-dependent	NULL
enhancer	NULL
activity	NULL
.	NULL

Further	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
ACaM-AI	NULL
on	NULL
induction	NULL
of	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
like	NULL
that	NULL
of	NULL
the	NULL
Ca*+	NULL
ionophore	NULL
,	NULL
is	NULL
sensitive	NULL
to	NULL
FK-506	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
compare	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
14	NULL
and	NULL
15	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
ACaM-AI	NULL
is	NULL
through	NULL
its	NULL
phosphatase	NULL
activity	NULL
rather	NULL
than	NULL
any	NULL
non-specific	NULL
effect	NULL
of	NULL
mutant	NULL
protein	NULL
over-expression	NULL
.	NULL

Note	NULL
that	NULL
in	NULL
all	NULL
cases	NULL
the	NULL
effects	NULL
of	NULL
both	NULL
PMA	NULL
and	NULL
calcineurin	NULL
are	NULL
specific	NULL
for	NULL
NF-xB	NULL
.	NULL

As	NULL
expected	NULL
(	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
,	NULL
Oct-1	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
any	NULL
treatment	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
lanes	NULL
8-12	NULL
and	NULL
20-24	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
a	NULL
rise	NULL
in	NULL
intracellular	NULL
activates	NULL
calcineurin	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
enhances	NULL
PMA-dependent	NULL
induction	NULL
of	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
thus	NULL
of	NULL
an	NULL
NF-xB-dependent	NULL
enhancer	NULL
.	NULL

The	NULL
NF-xB	NULL
induced	NULL
by	NULL
calcineurin	NULL
consists	NULL
of	NULL
p50/p65	NULL
heterodimers	NULL
Members	NULL
of	NULL
a	NULL
family	NULL
of	NULL
DNA	NULL
binding	NULL
proteins	NULL
,	NULL
consisting	NULL
most	NULL
notably	NULL
of	NULL
p50	NULL
,	NULL
p65	NULL
and	NULL
c-Rel	NULL
,	NULL
are	NULL
known	NULL
to	NULL
have	NULL
relatively	NULL
high	NULL
affinity	NULL
for	NULL
the	NULL
DNA	NULL
sequences	NULL
defined	NULL
as	NULL
NF-xB	NULL
binding	NULL
sites	NULL
(	NULL
Baeuerle	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
have	NULL
been	NULL
observed	NULL
to	NULL
bind	NULL
DNA	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
dimeric	NULL
configurations	NULL
.	NULL

A	NULL
p50/p65	NULL
heterodimer	NULL
is	NULL
the	NULL
prototypic	NULL
NF-	NULL
863	NULL
B.Frantz	NULL
et	NULL
al	NULL
.	NULL

ACaM-Al	NULL
=	NULL
=	NULL
S	NULL
,	NULL
x	NULL
NL	NULL
is	NULL
o	NULL
Ss	NULL
ACaM-Al	NULL
+	NULL
+	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

A	NULL
graphic	NULL
representation	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
produced	NULL
by	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
pSRaMAD3	NULL
and	NULL
the	NULL
promoter-reporter-CAT	NULL
plasmids	NULL
pTAn.xB.6	NULL
(	NULL
A	NULL
)	NULL
,	NULL
pTAn.E.3	NULL
(	NULL
B	NULL
)	NULL
or	NULL
pTAn.IL	NULL
(	NULL
C	NULL
)	NULL
or	NULL
with	NULL
reporter	NULL
plasmid	NULL
pTAn.xB.6	NULL
without	NULL
(	NULL
-	NULL
)	NULL
or	NULL
with	NULL
(	NULL
+	NULL
)	NULL
without	NULL
(	NULL
D	NULL
)	NULL
or	NULL
with	NULL
(	NULL
E	NULL
)	NULL
the	NULL
calcineurin	NULL
expression	NULL
plasmids	NULL
pSRa4ACaM-AI	NULL
and	NULL
Transfected	NULL
cells	NULL
were	NULL
untreated	NULL
(	NULL
lI	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
&	NULL
)	NULL
or	NULL
PMA	NULL
+	NULL
ionomycin	NULL
(	NULL
MB	NULL
)	NULL
.	NULL

For	NULL
each	NULL
promoter	NULL
the	NULL
CAT	NULL
activity	NULL
induced	NULL
by	NULL
the	NULL
indicated	NULL
treatment	NULL
is	NULL
shown	NULL
relative	NULL
to	NULL
the	NULL
CAT	NULL
activity	NULL
of	NULL
the	NULL
0	NULL
ug	NULL
pSRaMAD3	NULL
control	NULL
induced	NULL
with	NULL
PMA	NULL
+ionomycin	NULL
,	NULL
which	NULL
was	NULL
set	NULL
to	NULL
100	NULL
.	NULL

2.5	NULL
ug	NULL
of	NULL
pTAn.xB.6	NULL
or	NULL
pTAn.E.3	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
pTAn.IL	NULL
were	NULL
used	NULL
and	NULL
for	NULL
the	NULL
experiments	NULL
represented	NULL
by	NULL
panels	NULL
A-C	NULL
the	NULL
indicated	NULL
quantities	NULL
of	NULL
pSRaMAD3	NULL
were	NULL
used	NULL
,	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
in	NULL
the	NULL
transfection	NULL
being	NULL
maintained	NULL
by	NULL
varying	NULL
the	NULL
concentration	NULL
of	NULL
pSRa	NULL
.	NULL

The	NULL
titrations	NULL
of	NULL
IxB	NULL
were	NULL
repeated	NULL
three	NULL
times	NULL
,	NULL
each	NULL
yielding	NULL
the	NULL
same	NULL
trend	NULL
demonstrated	NULL
by	NULL
panels	NULL
A-C	NULL
.	NULL

Panels	NULL
D	NULL
and	NULL
E	NULL
are	NULL
single	NULL
representative	NULL
points	NULL
taken	NULL
from	NULL
an	NULL
experiment	NULL
in	NULL
which	NULL
pSRaMAD3	NULL
was	NULL
titrated	NULL
into	NULL
transfections	NULL
with	NULL
or	NULL
without	NULL
a	NULL
constant	NULL
concentration	NULL
of	NULL
pSRa4ACaM-AI	NULL
and	NULL
pSReCaNB	NULL
.	NULL

To	NULL
simplify	NULL
presentation	NULL
we	NULL
selected	NULL
a	NULL
point	NULL
in	NULL
the	NULL
titration	NULL
at	NULL
which	NULL
both	NULL
IxB-dependent	NULL
inhibition	NULL
of	NULL
enhancer	NULL
activity	NULL
and	NULL
reversal	NULL
by	NULL
calcineurin	NULL
were	NULL
observed	NULL
.	NULL

At	NULL
high	NULL
concentrations	NULL
of	NULL
pSRaMAD3	NULL
calcineurin	NULL
no	NULL
longer	NULL
reverses	NULL
inhibition	NULL
of	NULL
NF-xB-dependent	NULL
enhancer	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
represented	NULL
by	NULL
panels	NULL
D	NULL
and	NULL
E	NULL
,	NULL
1.25	NULL
ug	NULL
of	NULL
pSRaMAD3	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
pSRa4ACaM-AlI	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
pSRoCaNB	NULL
were	NULL
used	NULL
where	NULL
indicated	NULL
,	NULL
and	NULL
again	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
in	NULL
the	NULL
transfection	NULL
was	NULL
maintained	NULL
by	NULL
addition	NULL
of	NULL
pSR	NULL
«	NULL
.	NULL

xB	NULL
,	NULL
and	NULL
it	NULL
normally	NULL
exists	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
uninduced	NULL
non-B	NULL
cells	NULL
in	NULL
a	NULL
non-DNA	NULL
binding	NULL
state	NULL
complexed	NULL
with	NULL
a	NULL
third	NULL
protein	NULL
,	NULL
IxB	NULL
,	NULL
the	NULL
inhibitor	NULL
of	NULL
NF-xB	NULL
.	NULL

This	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
can	NULL
be	NULL
released	NULL
by	NULL
treating	NULL
cytoplasm	NULL
from	NULL
uninduced	NULL
cells	NULL
with	NULL
deoxycholate	NULL
(	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1988a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
NF-xB-like	NULL
DNA	NULL
binding	NULL
activity	NULL
observed	NULL
in	NULL
Figure	NULL
2A	NULL
we	NULL
treated	NULL
the	NULL
cytosolic	NULL
fraction	NULL
from	NULL
uninduced	NULL
Jurkat	NULL
cells	NULL
with	NULL
deoxycholate	NULL
(	NULL
Figure	NULL
2B	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
revealing	NULL
NF-xB	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
the	NULL
deoxycholate-induced	NULL
cytoplasmic	NULL
activity	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
(	NULL
ionomycin+PMA	NULL
)	NULL
-induced	NULL
nuclear	NULL
species	NULL
(	NULL
Figure	NULL
2B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
pre-incubation	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
(	NULL
ionomycin+PMA	NULL
)	NULL
-treated	NULL
cells	NULL
with	NULL
antibodies	NULL
to	NULL
the	NULL
NF-xB	NULL
subunits	NULL
p65	NULL
(	NULL
Figure	NULL
2C	NULL
,	NULL
lanes	NULL
1-3	NULL
)	NULL
and	NULL
p50	NULL
(	NULL
Figure	NULL
2D	NULL
,	NULL
lanes	NULL
1-3	NULL
)	NULL
specifically	NULL
eliminated	NULL
a	NULL
large	NULL
proportion	NULL
of	NULL
the	NULL
induced	NULL
DNA	NULL
binding	NULL
complex	NULL
and	NULL
caused	NULL
the	NULL
appearance	NULL
of	NULL
new	NULL
,	NULL
diffuse	NULL
complexes	NULL
that	NULL
had	NULL
lower	NULL
mobility	NULL
.	NULL

The	NULL
p65-specific	NULL
antibody	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
peptide	NULL
unique	NULL
to	NULL
the	NULL
p65	NULL
protein	NULL
.	NULL

The	NULL
p50	NULL
antibody	NULL
was	NULL
raised	NULL
against	NULL
full	NULL
length	NULL
p50	NULL
protein	NULL
and	NULL
has	NULL
been	NULL
demonstrated	NULL
not	NULL
to	NULL
cross-react	NULL
with	NULL
other	NULL
Rel-related	NULL
proteins	NULL
(	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
;	NULL
similar	NULL
864	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
antibodies	NULL
raised	NULL
against	NULL
the	NULL
nuclear	NULL
localization	NULL
signal	NULL
of	NULL
p50	NULL
which	NULL
is	NULL
conserved	NULL
between	NULL
p50	NULL
and	NULL
p49/p50B	NULL
(	NULL
Schmid	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
but	NULL
not	NULL
other	NULL
Rel	NULL
proteins	NULL
.	NULL

Taken	NULL
together	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
in	NULL
Jurkat	NULL
cells	NULL
calcineurin	NULL
enhances	NULL
PMA-dependent	NULL
activation	NULL
of	NULL
the	NULL
prototypic	NULL
p50/p65	NULL
NF-xB	NULL
transcription	NULL
factor	NULL
.	NULL

Calcineurin	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
IxB	NULL
There	NULL
are	NULL
several	NULL
ways	NULL
in	NULL
which	NULL
calcineurin	NULL
could	NULL
act	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
induce	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
do	NULL
not	NULL
depend	NULL
on	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

The	NULL
p50	NULL
(	NULL
50	NULL
kDa	NULL
)	NULL
subunit	NULL
of	NULL
NF-xB	NULL
is	NULL
derived	NULL
from	NULL
a	NULL
105	NULL
kDa	NULL
precursor	NULL
protein	NULL
(	NULL
Fan	NULL
and	NULL
Maniatis	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
rate	NULL
of	NULL
processing	NULL
of	NULL
precursors	NULL
to	NULL
p50-related	NULL
proteins	NULL
could	NULL
be	NULL
increased	NULL
by	NULL
calcineurin	NULL
,	NULL
generating	NULL
higher	NULL
levels	NULL
of	NULL
cytoplasmic	NULL
NF-xB	NULL
while	NULL
PMA	NULL
would	NULL
be	NULL
required	NULL
to	NULL
release	NULL
the	NULL
NF-xB	NULL
from	NULL
IxB	NULL
(	NULL
Ghosh	NULL
and	NULL
Baltimore	NULL
,	NULL
1990	NULL
;	NULL
Shirakawa	NULL
and	NULL
Mizel	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
PMA	NULL
alone	NULL
could	NULL
stimulate	NULL
inactivation	NULL
of	NULL
IxB	NULL
at	NULL
some	NULL
rate	NULL
and	NULL
calcineurin	NULL
could	NULL
increase	NULL
that	NULL
rate	NULL
.	NULL

Other	NULL
calcineurin-dependent	NULL
mechanisms	NULL
of	NULL
increasing	NULL
the	NULL
amount	NULL
of	NULL
NF-xB	NULL
released	NULL
by	NULL
PMA	NULL
,	NULL
such	NULL
as	NULL
increasing	NULL
the	NULL
rate	NULL
of	NULL
subunit	NULL
synthesis	NULL
,	NULL
would	NULL
entail	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

To	NULL
distinguish	NULL
between	NULL
a	NULL
pre-	NULL
and	NULL
post-synthetic	NULL
mechanism	NULL
of	NULL
calcineurin	NULL
action	NULL
we	NULL
measured	NULL
the	NULL
level	NULL
of	NULL
nuclear	NULL
NF-xB	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
after	NULL
cycloheximide	NULL
pretreatment	NULL
,	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
FK-506	NULL
(	NULL
Figure	NULL
2E	NULL
)	NULL
.	NULL

Cycloheximide	NULL
treatment	NULL
did	NULL
not	NULL
prevent	NULL
the	NULL
ionomycin-dependent	NULL
enhancement	NULL
of	NULL
PMA-induced	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Figure	NULL
2E	NULL
,	NULL
compare	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
the	NULL
PMA-dependent	NULL
induction	NULL
is	NULL
resistant	NULL
to	NULL
FK-506	NULL
(	NULL
Figure	NULL
2E	NULL
,	NULL
compare	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
and	NULL
the	NULL
ionomycin	NULL
effect	NULL
is	NULL
still	NULL
completely	NULL
sensitive	NULL
to	NULL
the	NULL
drug	NULL
(	NULL
Figure	NULL
2E	NULL
,	NULL
compare	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
NF-xB	NULL
by	NULL
a	NULL
post-translational	NULL
event	NULL
might	NULL
be	NULL
accomplished	NULL
by	NULL
calcineurin	NULL
stimulating	NULL
an	NULL
increase	NULL
in	NULL
either	NULL
p50	NULL
precursor	NULL
processing	NULL
or	NULL
IxB	NULL
inactivation	NULL
.	NULL

Since	NULL
others	NULL
have	NULL
observed	NULL
only	NULL
low	NULL
levels	NULL
of	NULL
proteolytic	NULL
processing	NULL
of	NULL
p105	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
PHA	NULL
(	NULL
Mercurio	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
we	NULL
decided	NULL
to	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
calcineurin	NULL
on	NULL
IxB	NULL
function	NULL
.	NULL

One	NULL
of	NULL
the	NULL
prevalent	NULL
species	NULL
of	NULL
mammalian	NULL
IxB	NULL
(	NULL
IxBa	NULL
)	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
cDNA	NULL
identified	NULL
as	NULL
MAD3	NULL
(	NULL
Haskill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
transient	NULL
transfection	NULL
experiments	NULL
expression	NULL
of	NULL
a	NULL
cDNA	NULL
encoding	NULL
the	NULL
c-Rel-associated	NULL
IxB	NULL
,	NULL
pp40	NULL
,	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
decrease	NULL
expression	NULL
of	NULL
NF-xB-dependent	NULL
promoters	NULL
(	NULL
Inoue	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
our	NULL
Jurkat	NULL
cells	NULL
co-transfection	NULL
of	NULL
an	NULL
expression	NULL
vector	NULL
encoding	NULL
IxB/MAD3	NULL
inhibited	NULL
NF-xB-dependent	NULL
promoter	NULL
activity	NULL
80	NULL
%	NULL
without	NULL
inhibiting	NULL
activity	NULL
of	NULL
an	NULL
IL-2E-dependent	NULL
promoter	NULL
(	NULL
Figure	NULL
3A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
promoter	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
co-transfection	NULL
of	NULL
the	NULL
IxB/MAD3	NULL
cDNA	NULL
,	NULL
directly	NULL
demonstrating	NULL
the	NULL
importance	NULL
of	NULL
NF-xB	NULL
in	NULL
IL-2	NULL
transcription	NULL
(	NULL
Figure	NULL
3C	NULL
)	NULL
.	NULL

If	NULL
calcineurin	NULL
induces	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
by	NULL
stimulating	NULL
the	NULL
inactivation	NULL
of	NULL
IxB	NULL
,	NULL
and	NULL
if	NULL
calcineurin	NULL
activity	NULL
is	NULL
limiting	NULL
for	NULL
the	NULL
inactivation	NULL
of	NULL
IxB	NULL
,	NULL
then	NULL
over-expression	NULL
of	NULL
calcineurin	NULL
should	NULL
compensate	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
MAD3	NULL
cDNA	NULL
and	NULL
prevent	NULL
the	NULL
MAD3-dependent	NULL
inhibition	NULL
of	NULL
NF-xB-dependent	NULL
promoter	NULL
activity	NULL
.	NULL

Co-transfection	NULL
of	NULL
an	NULL
appropriate	NULL
concentration	NULL
of	NULL
IxB	NULL
expression	NULL
plasmid	NULL
inhibited	NULL
60-70	NULL
%	NULL
of	NULL
PMA-	NULL
or	NULL
(	NULL
PMA	NULL
+	NULL
ionomycin	NULL
)	NULL
-induced	NULL
NF-xB-dependent	NULL
enhancer	NULL
activity	NULL
(	NULL
Figure	NULL
3A	NULL
and	NULL
D	NULL
)	NULL
.	NULL

When	NULL
ACaM-AI	NULL
was	NULL
included	NULL
in	NULL
the	NULL
transfection	NULL
(	NULL
Figure	NULL
3E	NULL
)	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
IxB	NULL
expression	NULL
plasmid	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
PMA	NULL
induction	NULL
and	NULL
only	NULL
slightly	NULL
inhibited	NULL
PMA	NULL
and	NULL
ionomycin	NULL
induction	NULL
of	NULL
NF-xB-dependent	NULL
enhancer	NULL
activity	NULL
.	NULL

Increased	NULL
concentrations	NULL
of	NULL
IxB	NULL
caused	NULL
greater	NULL
inhibition	NULL
of	NULL
the	NULL
NF-xB-dependent	NULL
enhancer	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
and	NULL
ACaM-AI	NULL
can	NULL
no	NULL
longer	NULL
reverse	NULL
its	NULL
inhibitory	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
calcineurin	NULL
induces	NULL
NF-xB	NULL
by	NULL
participating	NULL
in	NULL
the	NULL
inactivation	NULL
of	NULL
IxB	NULL
,	NULL
but	NULL
because	NULL
we	NULL
are	NULL
measuring	NULL
IxB	NULL
activity	NULL
indirectly	NULL
,	NULL
other	NULL
explanations	NULL
can	NULL
not	NULL
be	NULL
ruled	NULL
out	NULL
by	NULL
this	NULL
experiment	NULL
.	NULL

We	NULL
therefore	NULL
proceeded	NULL
to	NULL
measure	NULL
directly	NULL
the	NULL
effect	NULL
of	NULL
calcineurin	NULL
activity	NULL
on	NULL
IxB	NULL
protein	NULL
.	NULL

Events	NULL
which	NULL
induce	NULL
nuclear	NULL
localization	NULL
of	NULL
NF-xB	NULL
also	NULL
cause	NULL
degradation	NULL
of	NULL
IxB	NULL
protein	NULL
(	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Sun	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

To	NULL
demonstrate	NULL
directly	NULL
a	NULL
calcineurin-dependent	NULL
effect	NULL
on	NULL
IxB	NULL
we	NULL
measured	NULL
the	NULL
level	NULL
of	NULL
endogenous	NULL
IxB	NULL
in	NULL
Jurkat	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

FK-506	NULL
inhibited	NULL
the	NULL
ionomycin-dependent	NULL
decrease	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
IxB	NULL
(	NULL
Figure	NULL
4A	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

To	NULL
prove	NULL
that	NULL
the	NULL
reduction	NULL
of	NULL
IxB	NULL
induced	NULL
by	NULL
Calcineurin	NULL
stimulates	NULL
inactivation	NULL
of	NULL
IxB	NULL
A	NULL
(	NULL
J	NULL
-	NULL
8	NULL
&	NULL
-s	NULL
an	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Assay	NULL
for	NULL
endogenous	NULL
IxB	NULL
by	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blot	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
15	NULL
min	NULL
as	NULL
indicated	NULL
:	NULL
p	NULL
,	NULL
PMA	NULL
;	NULL
i	NULL
,	NULL
ionomycin	NULL
;	NULL
5	NULL
,	NULL
FK-506	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
detergent	NULL
lysis	NULL
and	NULL
IxB	NULL
was	NULL
precipitated	NULL
from	NULL
the	NULL
extracts	NULL
with	NULL
rabbit	NULL
antiserum	NULL
prepared	NULL
against	NULL
bacterially	NULL
produced	NULL
recombinant	NULL
MAD3	NULL
.	NULL

Precipitates	NULL
were	NULL
further	NULL
fractionated	NULL
by	NULL
denaturing	NULL
PAGE	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
PVDF	NULL
membrane	NULL
.	NULL

IxB	NULL
was	NULL
visualized	NULL
by	NULL
immunostaining	NULL
with	NULL
the	NULL
MAD3	NULL
antiserum	NULL
.	NULL

IxB	NULL
is	NULL
marked	NULL
with	NULL
an	NULL
arrow	NULL
,	NULL
a	NULL
non-specific	NULL
protein	NULL
that	NULL
cross-reacts	NULL
with	NULL
this	NULL
antiserum	NULL
is	NULL
indicated	NULL
by	NULL
'ns	NULL
'	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Assay	NULL
for	NULL
transfected	NULL
IxB/MAD3-hisg	NULL
by	NULL
NiZ*	NULL
-agarose	NULL
precipitation	NULL
and	NULL
Western	NULL
blot	NULL
.	NULL

For	NULL
each	NULL
lane	NULL
108	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
12.5	NULL
ug	NULL
of	NULL
pSRuMAD3-hisg	NULL
and	NULL
the	NULL
calcineurin	NULL
expression	NULL
plasmids	NULL
pSRo4ACaM-AI	NULL
(	NULL
100	NULL
ug	NULL
)	NULL
and	NULL
pSRaCaNB	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
16	NULL
h	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
PMA	NULL
and	NULL
FK-506	NULL
as	NULL
indicated	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
guanidinium	NULL
lysis	NULL
and	NULL
the	NULL
IxB/MAD3-his	NULL
,	NULL
was	NULL
precipitated	NULL
with	NULL
-agarose	NULL
and	NULL
visualized	NULL
by	NULL
immunostaining	NULL
with	NULL
the	NULL
MAD3	NULL
antiserum	NULL
as	NULL
above	NULL
.	NULL

Bacterially	NULL
produced	NULL
IxB	NULL
(	NULL
rIxB	NULL
)	NULL
,	NULL
marked	NULL
with	NULL
an	NULL
arrow	NULL
,	NULL
is	NULL
present	NULL
in	NULL
lane	NULL
5	NULL
;	NULL
a	NULL
non-specific	NULL
protein	NULL
that	NULL
precipitates	NULL
with	NULL
Ni	NULL
#	NULL
+-agarose	NULL
and	NULL
cross-reacts	NULL
with	NULL
the	NULL
antiserum	NULL
is	NULL
indicated	NULL
by	NULL
'ns	NULL
'	NULL
.	NULL

ionomycin	NULL
results	NULL
from	NULL
calcineurin	NULL
activity	NULL
we	NULL
transiently	NULL
co-expressed	NULL
an	NULL
IxB/MAD3-his4	NULL
fusion	NULL
protein	NULL
and	NULL
ACaM-AI	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
compared	NULL
the	NULL
levels	NULL
of	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
FK-506	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

The	NULL
calcineurin	NULL
activity	NULL
provided	NULL
by	NULL
ACaM-AI	NULL
significantly	NULL
increased	NULL
degradation	NULL
of	NULL
IxB/MAD3-his4	NULL
initiated	NULL
by	NULL
PMA	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
with	NULL
induction	NULL
of	NULL
NF-xB-dependent	NULL
enhancer	NULL
activity	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
nuclear	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
the	NULL
ionomycin-dependent	NULL
,	NULL
FK-506-sensitive	NULL
reduction	NULL
of	NULL
cytoplasmic	NULL
IxB	NULL
can	NULL
be	NULL
fully	NULL
explained	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
calcineurin	NULL
phosphatase	NULL
activity	NULL
resulting	NULL
from	NULL
increased	NULL
levels	NULL
of	NULL
intracellular	NULL
Ca**	NULL
.	NULL

A	NULL
comparison	NULL
of	NULL
the	NULL
data	NULL
in	NULL
Figures	NULL
1C	NULL
(	NULL
PMA	NULL
without	NULL
or	NULL
with	NULL
ionomycin	NULL
and	NULL
2A	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
with	NULL
those	NULL
in	NULL
Figure	NULL
4A	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
would	NULL
seem	NULL
to	NULL
suggest	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
calcineurin	NULL
on	NULL
reduction	NULL
of	NULL
IxB	NULL
might	NULL
not	NULL
be	NULL
as	NULL
great	NULL
as	NULL
its	NULL
effect	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
NF-xB-dependent	NULL
transcription	NULL
or	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Our	NULL
experiments	NULL
do	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
calcineurin	NULL
can	NULL
activate	NULL
NF-xB-dependent	NULL
transcription	NULL
activation	NULL
by	NULL
mechanisms	NULL
in	NULL
addition	NULL
to	NULL
reducing	NULL
the	NULL
amount	NULL
of	NULL
IxB	NULL
.	NULL

However	NULL
,	NULL
the	NULL
apparent	NULL
discrepency	NULL
can	NULL
be	NULL
explained	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
considering	NULL
differences	NULL
in	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
events	NULL
being	NULL
assayed	NULL
in	NULL
the	NULL
different	NULL
experiments	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
transcription	NULL
activity	NULL
or	NULL
DNA	NULL
binding	NULL
activity	NULL
is	NULL
apparent	NULL
as	NULL
an	NULL
accumulation	NULL
of	NULL
material	NULL
,	NULL
and	NULL
so	NULL
an	NULL
integration	NULL
of	NULL
the	NULL
signal	NULL
across	NULL
time	NULL
is	NULL
inherent	NULL
in	NULL
a	NULL
single	NULL
measurement	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
matter	NULL
how	NULL
effective	NULL
the	NULL
events	NULL
causing	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
IxB	NULL
are	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
IxB	NULL
can	NULL
not	NULL
decrease	NULL
beyond	NULL
zero	NULL
;	NULL
however	NULL
,	NULL
the	NULL
rate	NULL
at	NULL
which	NULL
IxB	NULL
is	NULL
eliminated	NULL
or	NULL
the	NULL
duration	NULL
of	NULL
its	NULL
reduction	NULL
can	NULL
be	NULL
affected	NULL
as	NULL
well	NULL
and	NULL
these	NULL
changes	NULL
would	NULL
not	NULL
be	NULL
apparent	NULL
from	NULL
a	NULL
single	NULL
time	NULL
point	NULL
.	NULL

Thus	NULL
if	NULL
calcineurin	NULL
activity	NULL
causes	NULL
865	NULL
B.Frantz	NULL
et	NULL
al	NULL
.	NULL

either	NULL
a	NULL
more	NULL
rapid	NULL
or	NULL
a	NULL
longer-lived	NULL
reduction	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
IxB	NULL
the	NULL
result	NULL
will	NULL
be	NULL
an	NULL
observed	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
nuclear	NULL
NF-xB	NULL
,	NULL
related	NULL
to	NULL
both	NULL
the	NULL
extent	NULL
of	NULL
IxB	NULL
degradation	NULL
and	NULL
its	NULL
duration	NULL
.	NULL

However	NULL
,	NULL
the	NULL
change	NULL
in	NULL
NF-xB	NULL
is	NULL
an	NULL
indirect	NULL
measure	NULL
;	NULL
a	NULL
direct	NULL
measure	NULL
would	NULL
require	NULL
a	NULL
time	NULL
course	NULL
of	NULL
IxB	NULL
degradation	NULL
and	NULL
resynthesis	NULL
.	NULL

Such	NULL
an	NULL
experiment	NULL
is	NULL
shown	NULL
in	NULL
Figure	NULL
5	NULL
.	NULL

It	NULL
is	NULL
apparent	NULL
that	NULL
co-treatment	NULL
with	NULL
ionomycin	NULL
causes	NULL
the	NULL
degradation	NULL
of	NULL
IxB	NULL
to	NULL
occur	NULL
more	NULL
quickly	NULL
and	NULL
to	NULL
a	NULL
greater	NULL
degree	NULL
than	NULL
treatment	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
that	NULL
both	NULL
of	NULL
these	NULL
effects	NULL
be	NULL
taken	NULL
into	NULL
account	NULL
when	NULL
comparing	NULL
the	NULL
increase	NULL
in	NULL
NF-xB-dependent	NULL
transcription	NULL
and	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
activity	NULL
caused	NULL
by	NULL
calcineurin	NULL
with	NULL
its	NULL
effects	NULL
on	NULL
IxB	NULL
.	NULL

It	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
inactivation	NULL
of	NULL
IxB	NULL
is	NULL
a	NULL
two-step	NULL
process	NULL
during	NULL
which	NULL
IxB	NULL
is	NULL
first	NULL
covalently	NULL
modified	NULL
and	NULL
then	NULL
rapidly	NULL
degraded	NULL
(	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Calcineurin	NULL
might	NULL
increase	NULL
the	NULL
rate	NULL
of	NULL
IxB	NULL
degradation	NULL
by	NULL
stimulating	NULL
either	NULL
step	NULL
.	NULL

These	NULL
alternative	NULL
possibilities	NULL
can	NULL
not	NULL
be	NULL
distinguished	NULL
by	NULL
the	NULL
experiments	NULL
described	NULL
above	NULL
as	NULL
we	NULL
saw	NULL
no	NULL
evidence	NULL
of	NULL
a	NULL
modified	NULL
version	NULL
of	NULL
either	NULL
endogenous	NULL
or	NULL
transiently	NULL
expressed	NULL
IxB	NULL
in	NULL
response	NULL
to	NULL
either	NULL
PMA	NULL
treatment	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
calcineurin	NULL
activation	NULL
(	NULL
Figure	NULL
4A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
distinguish	NULL
between	NULL
modification	NULL
and	NULL
degradation	NULL
as	NULL
the	NULL
step	NULL
at	NULL
which	NULL
calcineurin	NULL
acts	NULL
we	NULL
overwhelmed	NULL
the	NULL
degradation	NULL
pathway	NULL
by	NULL
increasing	NULL
the	NULL
amount	NULL
of	NULL
IxB	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
Jurkat	NULL
cells	NULL
to	NULL
extremely	NULL
high	NULL
levels	NULL
.	NULL

If	NULL
calcineurin	NULL
increases	NULL
the	NULL
rate	NULL
of	NULL
IxB	NULL
modification	NULL
we	NULL
might	NULL
then	NULL
observe	NULL
the	NULL
short-lived	NULL
intermediate	NULL
,	NULL
dependent	NULL
on	NULL
calcineurin	NULL
activity	NULL
.	NULL

If	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
calcineurin	NULL
stimulates	NULL
the	NULL
proteolysis	NULL
there	NULL
could	NULL
be	NULL
no	NULL
calcineurin-dependent	NULL
increase	NULL
in	NULL
this	NULL
species	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
10	NULL
times	NULL
more	NULL
IxB/MAD3-hisg	NULL
cDNA	NULL
than	NULL
in	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Figure	NULL
4B	NULL
there	NULL
was	NULL
virtually	NULL
no	NULL
reduction	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
cytoplasmic	NULL
IxB	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
calcineurin	NULL
activity	NULL
(	NULL
Figure	NULL
6A	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
;	NULL
however	NULL
,	NULL
a	NULL
novel	NULL
,	NULL
more	NULL
slowly	NULL
migrating	NULL
species	NULL
of	NULL
IxB	NULL
appeared	NULL
under	NULL
these	NULL
conditions	NULL
(	NULL
Figure	NULL
6A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

This	NULL
species	NULL
has	NULL
a	NULL
similar	NULL
mobility	NULL
to	NULL
a	NULL
modified	NULL
endogenous	NULL
IxB	NULL
that	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
after	NULL
treatment	NULL
with	NULL
other	NULL
inducers	NULL
of	NULL
NF-xB	NULL
(	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
more	NULL
slowly	NULL
migrating	NULL
species	NULL
was	NULL
not	NULL
apparent	NULL
after	NULL
treatment	NULL
with	NULL
FK-506	NULL
(	NULL
Figure	NULL
6A	NULL
,	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
2	NULL
)	NULL
demonstrating	NULL
that	NULL
calcineurin	NULL
phosphatase	NULL
activity	NULL
participates	NULL
in	NULL
generating	NULL
this	NULL
form	NULL
of	NULL
IxB	NULL
.	NULL

This	NULL
species	NULL
of	NULL
IxB	NULL
was	NULL
eliminated	NULL
by	NULL
treatment	NULL
with	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
suggesting	NULL
that	NULL
it	NULL
results	NULL
from	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxB	NULL
.	NULL

A	NULL
simple	NULL
interpretation	NULL
of	NULL
these	NULL
data	NULL
is	NULL
that	NULL
calcineurin	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
IxB	NULL
by	NULL
co-activating	NULL
a	NULL
kinase	NULL
.	NULL

Further	NULL
speculation	NULL
about	NULL
the	NULL
mechanism	NULL
of	NULL
calcineurin	NULL
function	NULL
in	NULL
this	NULL
regard	NULL
will	NULL
have	NULL
to	NULL
await	NULL
phosphopeptide	NULL
mapping	NULL
of	NULL
IxB	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
with	NULL
calcineurin	NULL
as	NULL
well	NULL
as	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
calcineurin-responsive	NULL
kinase	NULL
.	NULL

Discussion	NULL
With	NULL
the	NULL
identification	NULL
of	NULL
calcineurin	NULL
as	NULL
the	NULL
CsA/FK-506-sensitive	NULL
enzyme	NULL
essential	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
Liu	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
numerous	NULL
observations	NULL
of	NULL
Ca	NULL
+*-dependent	NULL
,	NULL
FK-506/CsA-sensitive	NULL
promoter	NULL
activities	NULL
(	NULL
Kronke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Granelli-Piperno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
866	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Assay	NULL
for	NULL
endogenous	NULL
IxB	NULL
by	NULL
Western	NULL
blot	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
!	NULL
)	NULL

alone	NULL
or	NULL
both	NULL
PMA	NULL
and	NULL
ionomycin	NULL
and	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
after	NULL
treatment	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Equal	NULL
quantities	NULL
of	NULL
protein	NULL
from	NULL
these	NULL
whole	NULL
cell	NULL
extracts	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
,	NULL
transferred	NULL
to	NULL
membrane	NULL
and	NULL
probed	NULL
with	NULL
anti-MAD3	NULL
antiserum	NULL
.	NULL

Cells	NULL
labeled	NULL
as	NULL
O	NULL
min	NULL
were	NULL
untreated	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Assay	NULL
for	NULL
transfected	NULL
IxB/MAD3-hisg	NULL
by	NULL
Ni	NULL
#	NULL
Z+	NULL
-agarose	NULL
precipitation	NULL
and	NULL
Western	NULL
blot	NULL
.	NULL

10	NULL
%	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
pSRaMAD3-hisg	NULL
and	NULL
the	NULL
calcineurin	NULL
expression	NULL
plasmids	NULL
pSRa4ACaM-AI	NULL
(	NULL
100	NULL
ug	NULL
)	NULL
and	NULL
pSRaCaNB	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
16	NULL
h	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
10	NULL
min	NULL
as	NULL
indicated	NULL
:	NULL
p	NULL
,	NULL
PMA	NULL
;	NULL
i	NULL
,	NULL
ionomycin	NULL
;	NULL
5	NULL
,	NULL
FK-506	NULL
.	NULL

Extracts	NULL
were	NULL
prepared	NULL
and	NULL
IxB/MAD3-his	NULL
,	NULL
was	NULL
purified	NULL
and	NULL
visualized	NULL
as	NULL
in	NULL
Figure	NULL
4B	NULL
.	NULL

Normal	NULL
IxB/MAD3-hisg	NULL
is	NULL
marked	NULL
with	NULL
an	NULL
arrow	NULL
and	NULL
a	NULL
lower	NULL
mobility	NULL
species	NULL
is	NULL
marked	NULL
with	NULL
an	NULL
asterisk	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Calf	NULL
intestinal	NULL
alkaline	NULL
phosphate	NULL
treatment	NULL
of	NULL
Ni	NULL
*	NULL
-agarose	NULL
precipitated	NULL
IxB/MAD3-hiss	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
as	NULL
in	NULL
panel	NULL
A	NULL
and	NULL
treated	NULL
for	NULL
10	NULL
min	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
the	NULL
was	NULL
precipitated	NULL
from	NULL
PMA-treated	NULL
cells	NULL
it	NULL
was	NULL
divided	NULL
into	NULL
three	NULL
aliquots	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
treated	NULL
with	NULL
30	NULL
U	NULL
of	NULL
calf	NULL
intestinal	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
CIP	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
30	NULL
units	NULL
of	NULL
CIP	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
phosphatase	NULL
inhibitors	NULL
Na	NULL
;	NULL
VO4	NULL
and	NULL
NaF	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Gunter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Tocci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Randak	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Schmidt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Todd	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
imply	NULL
that	NULL
this	NULL
protein	NULL
phosphatase	NULL
is	NULL
a	NULL
key	NULL
co-inducer	NULL
of	NULL
either	NULL
a	NULL
variety	NULL
of	NULL
transcription	NULL
factors	NULL
or	NULL
a	NULL
single	NULL
,	NULL
broadly	NULL
acting	NULL
transcription	NULL
co-activator	NULL
.	NULL

The	NULL
FK-506/CsA-sensitive	NULL
induction	NULL
of	NULL
several	NULL
DNA	NULL
binding	NULL
factors	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
Ca	NULL
``	NULL
+*	NULL
and	NULL
PMA	NULL
(	NULL
Brabletz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Schmidt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
supports	NULL
the	NULL
former	NULL
conclusion	NULL
but	NULL
no	NULL
direct	NULL
evidence	NULL
has	NULL
yet	NULL
been	NULL
offered	NULL
.	NULL

Since	NULL
Ca°+*	NULL
activates	NULL
both	NULL
CsA/FK-506-sensitive	NULL
and	NULL
-resistant	NULL
signal	NULL
transduction	NULL
pathways	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
(	NULL
Mattila	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Altmeyer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
the	NULL
function	NULL
of	NULL
a	NULL
Ca*	NULL
*-activated	NULL
transcription	NULL
factor	NULL
might	NULL
appear	NULL
drug-sensitive	NULL
,	NULL
even	NULL
though	NULL
it	NULL
is	NULL
not	NULL
activated	NULL
by	NULL
calcineurin	NULL
,	NULL
because	NULL
it	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
function	NULL
of	NULL
another	NULL
,	NULL
calcineurin-activated	NULL
,	NULL
factor	NULL
.	NULL

This	NULL
potential	NULL
complexity	NULL
would	NULL
make	NULL
it	NULL
impossible	NULL
to	NULL
distinguish	NULL
,	NULL
simply	NULL
by	NULL
sensitivity	NULL
to	NULL
the	NULL
immunosuppressants	NULL
,	NULL
the	NULL
specific	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
activated	NULL
by	NULL
through	NULL
calcineurin	NULL
from	NULL
those	NULL
molecules	NULL
that	NULL
are	NULL
activated	NULL
by	NULL
Ca**	NULL
through	NULL
another	NULL
mechanism	NULL
but	NULL
which	NULL
are	NULL
dependent	NULL
on	NULL
calcineurin-mediated	NULL
events	NULL
for	NULL
their	NULL
function	NULL
.	NULL

Further	NULL
,	NULL
promoter	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
calcineurin	NULL
,	NULL
and	NULL
PMA	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
might	NULL
be	NULL
the	NULL
result	NULL
of	NULL
a	NULL
single	NULL
transcription	NULL
factor	NULL
requiring	NULL
all	NULL
three	NULL
stimuli	NULL
for	NULL
activation	NULL
,	NULL
or	NULL
of	NULL
promoter	NULL
activity	NULL
requiring	NULL
multiple	NULL
factors	NULL
,	NULL
each	NULL
activated	NULL
by	NULL
a	NULL
different	NULL
combination	NULL
of	NULL
stimuli	NULL
.	NULL

The	NULL
work	NULL
described	NULL
in	NULL
this	NULL
communication	NULL
was	NULL
undertaken	NULL
to	NULL
assess	NULL
whether	NULL
calcineurin	NULL
activation	NULL
can	NULL
account	NULL
for	NULL
all	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
free	NULL
intracellular	NULL
and	NULL
to	NULL
define	NULL
specific	NULL
calcineurin-mediated	NULL
events	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

To	NULL
achieve	NULL
this	NULL
goal	NULL
we	NULL
have	NULL
used	NULL
transient	NULL
transfection	NULL
of	NULL
a	NULL
Ca	NULL
``	NULL
*-independent	NULL
,	NULL
constitutively	NULL
active	NULL
form	NULL
of	NULL
calcineurin	NULL
,	NULL
ACaM-AlI	NULL
,	NULL
to	NULL
demonstrate	NULL
that	NULL
the	NULL
Ca*+-dependence	NULL
of	NULL
certain	NULL
events	NULL
can	NULL
either	NULL
be	NULL
attributed	NULL
to	NULL
the	NULL
requirement	NULL
for	NULL
calcineurin	NULL
activity	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
with	NULL
NF-xB	NULL
activation	NULL
,	NULL
or	NULL
a	NULL
requirement	NULL
for	NULL
both	NULL
calcineurin	NULL
activity	NULL
and	NULL
another	NULL
Ca*+*-dependent	NULL
event	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
with	NULL
the	NULL
NF-AT	NULL
and	NULL
OAP/Oct	NULL
enhancer	NULL
element	NULL
induction	NULL
.	NULL

We	NULL
are	NULL
also	NULL
able	NULL
to	NULL
demonstrate	NULL
that	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NF-xB	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
synergize	NULL
by	NULL
virtue	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
calcineurin	NULL
to	NULL
enhance	NULL
the	NULL
PMA-initiated	NULL
degradation	NULL
of	NULL
an	NULL
NF-xB	NULL
inhibitor	NULL
protein	NULL
(	NULL
IxB	NULL
)	NULL
.	NULL

Two	NULL
distinct	NULL
Ca	NULL
+-dependent	NULL
enzymes	NULL
participate	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
In	NULL
Jurkat	NULL
T	NULL
cells	NULL
accumulation	NULL
of	NULL
c-fos	NULL
mRNA	NULL
is	NULL
increased	NULL
by	NULL
treatment	NULL
with	NULL
Ca*+*	NULL
ionophore	NULL
(	NULL
Mattila	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

This	NULL
Ca**	NULL
response	NULL
is	NULL
not	NULL
mediated	NULL
by	NULL
calcineurin	NULL
since	NULL
it	NULL
can	NULL
not	NULL
be	NULL
inhibited	NULL
by	NULL
either	NULL
FK-506	NULL
or	NULL
CsA	NULL
.	NULL

Despite	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
c-fos	NULL
gene	NULL
product	NULL
is	NULL
a	NULL
component	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
,	NULL
which	NULL
is	NULL
believed	NULL
to	NULL
participate	NULL
in	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
both	NULL
alone	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992a	NULL
)	NULL
and	NULL
as	NULL
a	NULL
component	NULL
of	NULL
NF-AT	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992b	NULL
)	NULL
,	NULL
there	NULL
has	NULL
been	NULL
no	NULL
indication	NULL
that	NULL
this	NULL
non-calcineurin	NULL
,	NULL
Ca	NULL
``	NULL
event	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
IL-2	NULL
transcription	NULL
.	NULL

Through	NULL
use	NULL
of	NULL
the	NULL
Ca**+-independent	NULL
deletion	NULL
mutant	NULL
of	NULL
calcineurin	NULL
,	NULL
ACaM-AI	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
,	NULL
like	NULL
the	NULL
complex	NULL
IL-2	NULL
promoter	NULL
,	NULL
three	NULL
of	NULL
four	NULL
enhancer	NULL
elements	NULL
associated	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
can	NULL
not	NULL
be	NULL
maximally	NULL
activated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
calcineurin	NULL
alone	NULL
;	NULL
treatment	NULL
with	NULL
ionophore	NULL
is	NULL
also	NULL
required	NULL
(	NULL
Figure	NULL
1A	NULL
,	NULL
B	NULL
and	NULL
D	NULL
)	NULL
.	NULL

One	NULL
explanation	NULL
for	NULL
this	NULL
observation	NULL
is	NULL
that	NULL
a	NULL
non-calcineurin	NULL
,	NULL
Ca	NULL
``	NULL
*-dependent	NULL
event	NULL
results	NULL
in	NULL
the	NULL
production	NULL
or	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
such	NULL
as	NULL
c-Fos	NULL
)	NULL
that	NULL
are	NULL
necessary	NULL
but	NULL
not	NULL
sufficient	NULL
for	NULL
maximal	NULL
IL-2-	NULL
,	NULL
IL-2A¥-	NULL
,	NULL
IL-2E-	NULL
or	NULL
AP-l-dependent	NULL
promoter	NULL
activities	NULL
.	NULL

Another	NULL
possible	NULL
explanation	NULL
for	NULL
this	NULL
observation	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
IL-2	NULL
,	NULL
IL-2A	NULL
and	NULL
IL-2E	NULL
enhancers	NULL
,	NULL
is	NULL
that	NULL
transfection	NULL
of	NULL
ACaM-AI	NULL
provides	NULL
only	NULL
a	NULL
small	NULL
fraction	NULL
of	NULL
the	NULL
calcineurin	NULL
activity	NULL
obtained	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
ionomycin	NULL
.	NULL

However	NULL
,	NULL
we	NULL
think	NULL
this	NULL
possibility	NULL
is	NULL
unlikely	NULL
since	NULL
the	NULL
enhancer	NULL
element	NULL
which	NULL
depends	NULL
on	NULL
NF-xB	NULL
was	NULL
two	NULL
to	NULL
three	NULL
times	NULL
more	NULL
active	NULL
when	NULL
co-transfected	NULL
with	NULL
ACaM-AI	NULL
than	NULL
when	NULL
treated	NULL
with	NULL
ionomycin	NULL
and	NULL
was	NULL
not	NULL
further	NULL
activated	NULL
by	NULL
treatment	NULL
with	NULL
ionomycin	NULL
after	NULL
co-transfection	NULL
with	NULL
ACaM-AI	NULL
.	NULL

Therefore	NULL
we	NULL
conclude	NULL
that	NULL
ACaM-AI	NULL
co-transfection	NULL
provides	NULL
at	NULL
least	NULL
two	NULL
to	NULL
three	NULL
times	NULL
as	NULL
much	NULL
calcineurin	NULL
activity	NULL
as	NULL
treatment	NULL
with	NULL
ionomycin	NULL
and	NULL
thus	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
IL-2	NULL
,	NULL
IL-2A	NULL
and	NULL
IL-2E	NULL
enhancer	NULL
activities	NULL
observed	NULL
after	NULL
co-transfection	NULL
with	NULL
ACaM-AlI	NULL
and	NULL
treatment	NULL
with	NULL
ionomycin	NULL
can	NULL
not	NULL
be	NULL
the	NULL
result	NULL
of	NULL
activating	NULL
endogenous	NULL
,	NULL
wild-type	NULL
calcineurin	NULL
,	NULL
but	NULL
must	NULL
reflect	NULL
activation	NULL
of	NULL
a	NULL
non-calcineurin	NULL
,	NULL
Ca**+-dependent	NULL
pathway	NULL
of	NULL
transcription	NULL
activation	NULL
that	NULL
can	NULL
stimulate	NULL
specific	NULL
enhancer	NULL
elements	NULL
.	NULL

Calcineurin	NULL
stimulates	NULL
inactivation	NULL
of	NULL
IxB	NULL
As	NULL
noted	NULL
,	NULL
the	NULL
B-dependent	NULL
enhancer	NULL
is	NULL
two	NULL
to	NULL
three	NULL
times	NULL
more	NULL
active	NULL
in	NULL
PMA-treated	NULL
cells	NULL
that	NULL
have	NULL
been	NULL
transfected	NULL
with	NULL
ACaM-AI	NULL
than	NULL
in	NULL
control	NULL
transfected	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

This	NULL
strongly	NULL
suggests	NULL
that	NULL
in	NULL
these	NULL
cells	NULL
calcineurin	NULL
activity	NULL
limits	NULL
NF-xB	NULL
activity	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
the	NULL
IL-2A	NULL
element	NULL
is	NULL
more	NULL
active	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ACaM-AI	NULL
than	NULL
in	NULL
its	NULL
absence	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Thus	NULL
in	NULL
our	NULL
Jurkat	NULL
cells	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
element	NULL
is	NULL
also	NULL
limited	NULL
by	NULL
the	NULL
availability	NULL
of	NULL
active	NULL
calcineurin	NULL
.	NULL

By	NULL
the	NULL
converse	NULL
argument	NULL
,	NULL
activity	NULL
of	NULL
the	NULL
IL-2E	NULL
element	NULL
must	NULL
be	NULL
limited	NULL
by	NULL
some	NULL
other	NULL
activation	NULL
event	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

It	NULL
could	NULL
be	NULL
argued	NULL
that	NULL
the	NULL
NF-xB-dependent	NULL
enhancer	NULL
is	NULL
not	NULL
stimulated	NULL
by	NULL
treatment	NULL
with	NULL
ionomycin	NULL
after	NULL
co-transfection	NULL
with	NULL
ACaM-AI	NULL
because	NULL
either	NULL
the	NULL
transfection	NULL
process	NULL
itself	NULL
creates	NULL
a	NULL
signal	NULL
that	NULL
makes	NULL
treatment	NULL
with	NULL
ionomycin	NULL
superfluous	NULL
or	NULL
the	NULL
overexpression	NULL
of	NULL
a	NULL
constitutive	NULL
calcineurin	NULL
provides	NULL
increased	NULL
levels	NULL
of	NULL
intracellular	NULL
Ca*+	NULL
.	NULL

This	NULL
seems	NULL
unlikely	NULL
for	NULL
two	NULL
reasons	NULL
.	NULL

First	NULL
,	NULL
this	NULL
enhancer	NULL
is	NULL
dependent	NULL
on	NULL
ionomycin	NULL
treatment	NULL
for	NULL
maximal	NULL
activity	NULL
when	NULL
it	NULL
is	NULL
co-transfected	NULL
with	NULL
a	NULL
control	NULL
DNA	NULL
which	NULL
does	NULL
not	NULL
express	NULL
ACaM-AI	NULL
,	NULL
thus	NULL
the	NULL
transfection	NULL
process	NULL
itself	NULL
is	NULL
not	NULL
providing	NULL
a	NULL
signal	NULL
that	NULL
obviates	NULL
the	NULL
need	NULL
for	NULL
ionomycin	NULL
.	NULL

Second	NULL
,	NULL
since	NULL
the	NULL
IL-2	NULL
,	NULL
IL-2A	NULL
and	NULL
IL-2E	NULL
enhancers	NULL
all	NULL
demonstrate	NULL
a	NULL
requirement	NULL
for	NULL
ionomycin	NULL
co-stimulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
co-transfected	NULL
ACaM-AlI	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
mutant	NULL
calcineurin	NULL
is	NULL
not	NULL
causing	NULL
a	NULL
significant	NULL
rise	NULL
in	NULL
the	NULL
level	NULL
of	NULL
intracellular	NULL
Ca**	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
act1v1ty	NULL
of	NULL
the	NULL
IL-2A	NULL
element	NULL
is	NULL
completely	NULL
sensitive	NULL
to	NULL
both	NULL
FK-506	NULL
and	NULL
CsA	NULL
,	NULL
no	NULL
drug-sensitive	NULL
biochemical	NULL
event	NULL
relevant	NULL
to	NULL
this	NULL
element	NULL
has	NULL
yet	NULL
been	NULL
documented	NULL
.	NULL

Furthermore	NULL
,	NULL
there	NULL
is	NULL
no	NULL
direct	NULL
evidence	NULL
,	NULL
of	NULL
the	NULL
kind	NULL
we	NULL
have	NULL
provided	NULL
in	NULL
this	NULL
communication	NULL
,	NULL
demonstrating	NULL
the	NULL
role	NULL
of	NULL
calcineurin	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
NF-AT	NULL
(	NULL
IL-2E	NULL
)	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Thus	NULL
there	NULL
remain	NULL
unidentified	NULL
,	NULL
calcineurin-dependent	NULL
transcription	NULL
activation	NULL
events	NULL
which	NULL
function	NULL
through	NULL
IL-2	NULL
and	NULL
perhaps	NULL
also	NULL
through	NULL
IL-2E	NULL
.	NULL

Calcineurin	NULL
can	NULL
negatively	NULL
modulate	NULL
promoter	NULL
activity	NULL
Treatment	NULL
with	NULL
ionomycin	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
constitutive	NULL
mutant	NULL
calcineurin	NULL
has	NULL
a	NULL
deleterious	NULL
effect	NULL
on	NULL
activation	NULL
of	NULL
an	NULL
AP-1-dependent	NULL
enhancer	NULL
by	NULL
PMA	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
.	NULL

While	NULL
treatment	NULL
with	NULL
FK-506	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
enhancer	NULL
after	NULL
induction	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
FK-506	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
always	NULL
increases	NULL
promoter	NULL
activity	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
in	NULL
T	NULL
cells	NULL
AP-1-dependent	NULL
transcription	NULL
activation	NULL
can	NULL
be	NULL
both	NULL
positively	NULL
and	NULL
negatively	NULL
regulated	NULL
by	NULL
Ca**	NULL
:	NULL
negatively	NULL
through	NULL
calcineurin	NULL
and	NULL
positively	NULL
through	NULL
a	NULL
non-calcineurin	NULL
,	NULL
Ca*+-responsive	NULL
effector	NULL
.	NULL

Qualitatively	NULL
similar	NULL
data	NULL
have	NULL
been	NULL
reported	NULL
previously	NULL
,	NULL
though	NULL
with	NULL
greater	NULL
suppression	NULL
of	NULL
PMA	NULL
induction	NULL
by	NULL
ionomycin	NULL
,	NULL
and	NULL
only	NULL
recovery	NULL
to	NULL
PMA-induced	NULL
levels	NULL
by	NULL
treatment	NULL
with	NULL
FK-506	NULL
(	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
would	NULL
be	NULL
consistent	NULL
with	NULL
varying	NULL
ratios	NULL
of	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
cell	NULL
line	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
the	NULL
possibility	NULL
that	NULL
one	NULL
function	NULL
of	NULL
calcineurin	NULL
in	NULL
any	NULL
cell	NULL
type	NULL
may	NULL
be	NULL
negative	NULL
regulation	NULL
of	NULL
promoters	NULL
that	NULL
are	NULL
very	NULL
dependent	NULL
on	NULL
AP-1	NULL
for	NULL
activity	NULL
and	NULL
thus	NULL
that	NULL
FK-506	NULL
and	NULL
CsA	NULL
toxicities	NULL
could	NULL
result	NULL
from	NULL
transcription	NULL
activation	NULL
rather	NULL
than	NULL
suppression	NULL
.	NULL

867	NULL
B.Frantz	NULL
et	NULL
al	NULL
.	NULL

Calcineurin	NULL
activates	NULL
NF-xB	NULL
by	NULL
inactivating	NULL
IxB	NULL
NF-xB	NULL
is	NULL
a	NULL
paradigm	NULL
for	NULL
a	NULL
class	NULL
of	NULL
transcription	NULL
factors	NULL
which	NULL
can	NULL
initiate	NULL
a	NULL
cascade	NULL
of	NULL
transcription-dependent	NULL
events	NULL
,	NULL
such	NULL
as	NULL
is	NULL
required	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
Crabtree	NULL
,	NULL
1989	NULL
)	NULL
,	NULL
because	NULL
their	NULL
activation	NULL
is	NULL
due	NULL
to	NULL
release	NULL
from	NULL
inhibition	NULL
rather	NULL
than	NULL
de	NULL
novo	NULL
synthesis	NULL
(	NULL
Baeuerle	NULL
,	NULL
1991	NULL
;	NULL
Blank	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

This	NULL
transcription	NULL
factor	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
activating	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Hoyos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Shibuya	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Baumann	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Briegel	NULL
eral	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
(	NULL
and	NULL
Figure	NULL
3	NULL
)	NULL
as	NULL
well	NULL
as	NULL
numerous	NULL
other	NULL
promoters	NULL
,	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
(	NULL
Baeuerle	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

Therefore	NULL
understanding	NULL
how	NULL
calcineurin	NULL
activates	NULL
NF-xB	NULL
might	NULL
provide	NULL
generalizable	NULL
insights	NULL
into	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
this	NULL
transcription	NULL
factor	NULL
is	NULL
controlled	NULL
.	NULL

The	NULL
NF-xB-dependent	NULL
enhancer	NULL
,	NULL
like	NULL
the	NULL
others	NULL
tested	NULL
,	NULL
requires	NULL
both	NULL
PMA	NULL
and	NULL
Ca**	NULL
initiated	NULL
events	NULL
to	NULL
achieve	NULL
maximal	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
,	NULL
as	NULL
previously	NULL
observed	NULL
(	NULL
Mattila	NULL
eral	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
Ca°+	NULL
activation	NULL
of	NULL
the	NULL
NF-xB-dependent	NULL
enhancer	NULL
is	NULL
sensitive	NULL
to	NULL
FK-506	NULL
.	NULL

However	NULL
,	NULL
as	NULL
defined	NULL
by	NULL
the	NULL
extent	NULL
of	NULL
its	NULL
response	NULL
to	NULL
ACaM-AI	NULL
,	NULL
the	NULL
NF-xB-dependent	NULL
enhancer	NULL
is	NULL
unique	NULL
in	NULL
responding	NULL
to	NULL
Ca*+	NULL
only	NULL
through	NULL
calcineurin	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

Thus	NULL
NF-xB	NULL
activity	NULL
provides	NULL
the	NULL
simplest	NULL
available	NULL
assay	NULL
for	NULL
calcineurin	NULL
function	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
above	NULL
demonstrate	NULL
calcineurin-dependent	NULL
post-translational	NULL
activation	NULL
of	NULL
NF-xB	NULL
by	NULL
inactivation	NULL
of	NULL
IxB	NULL
.	NULL

Several	NULL
protein	NULL
kinases	NULL
inactivate	NULL
IxB	NULL
in	NULL
vitro	NULL
(	NULL
Ghosh	NULL
and	NULL
Baltimore	NULL
,	NULL
1990	NULL
;	NULL
Shirakawa	NULL
and	NULL
Mizel	NULL
,	NULL
1989	NULL
)	NULL
and	NULL
are	NULL
thought	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
constitute	NULL
the	NULL
first	NULL
demonstration	NULL
in	NULL
vivo	NULL
of	NULL
the	NULL
involvement	NULL
of	NULL
a	NULL
protein	NULL
phosphatase	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
through	NULL
inactivation	NULL
of	NULL
IxB	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
dephosphorylation	NULL
of	NULL
IxB-8	NULL
inactivates	NULL
it	NULL
(	NULL
Kerr	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Link	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
suggesting	NULL
that	NULL
this	NULL
class	NULL
of	NULL
IxB	NULL
may	NULL
be	NULL
a	NULL
substrate	NULL
for	NULL
calcineurin	NULL
.	NULL

However	NULL
,	NULL
the	NULL
FK-506-sensitive	NULL
appearance	NULL
of	NULL
a	NULL
phosphorylated	NULL
form	NULL
of	NULL
IxB	NULL
(	NULL
Figure	NULL
6A	NULL
and	NULL
B	NULL
)	NULL
suggests	NULL
the	NULL
possibility	NULL
that	NULL
calcineurin	NULL
activates	NULL
a	NULL
protein	NULL
kinase	NULL
,	NULL
which	NULL
inactivates	NULL
IxB	NULL
by	NULL
phosphorylation	NULL
.	NULL

While	NULL
there	NULL
are	NULL
no	NULL
data	NULL
yet	NULL
available	NULL
to	NULL
prove	NULL
that	NULL
the	NULL
modification	NULL
is	NULL
an	NULL
essential	NULL
prelude	NULL
to	NULL
degradation	NULL
of	NULL
IxB	NULL
,	NULL
and	NULL
thus	NULL
activation	NULL
of	NULL
NF-xB	NULL
,	NULL
the	NULL
events	NULL
required	NULL
to	NULL
cause	NULL
the	NULL
induction	NULL
of	NULL
nuclear	NULL
NF-xB	NULL
and	NULL
the	NULL
reduction	NULL
of	NULL
cytoplasmic	NULL
IxB	NULL
correlate	NULL
extremely	NULL
well	NULL
with	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
,	NULL
phosphorylated	NULL
IxB	NULL
species	NULL
.	NULL

A	NULL
model	NULL
explaining	NULL
the	NULL
participation	NULL
of	NULL
calcineurin	NULL
in	NULL
IxB	NULL
modification	NULL
as	NULL
well	NULL
as	NULL
its	NULL
dependence	NULL
on	NULL
PMA	NULL
for	NULL
activity	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
regulated	NULL
kinase	NULL
(	NULL
Minshull	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
kinase	NULL
must	NULL
be	NULL
phosphorylated	NULL
at	NULL
certain	NULL
amino	NULL
acids	NULL
and	NULL
dephosphorylated	NULL
at	NULL
others	NULL
in	NULL
order	NULL
to	NULL
achieve	NULL
maximal	NULL
activity	NULL
.	NULL

Perhaps	NULL
a	NULL
similarly	NULL
regulated	NULL
kinase	NULL
modifies	NULL
IxB	NULL
at	NULL
a	NULL
certain	NULL
rate	NULL
when	NULL
specific	NULL
sites	NULL
are	NULL
phosphorylated	NULL
by	NULL
a	NULL
kinase	NULL
activated	NULL
by	NULL
PMA	NULL
(	NULL
e.g	NULL
.	NULL

protein	NULL
kinase	NULL
C	NULL
)	NULL
and	NULL
at	NULL
a	NULL
higher	NULL
rate	NULL
when	NULL
dephosphorylated	NULL
at	NULL
other	NULL
sites	NULL
by	NULL
activation	NULL
of	NULL
calcineurin	NULL
.	NULL

This	NULL
would	NULL
be	NULL
one	NULL
mechanism	NULL
by	NULL
which	NULL
two	NULL
independent	NULL
signals	NULL
emanating	NULL
from	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
could	NULL
be	NULL
integrated	NULL
and	NULL
regulated	NULL
.	NULL

NF-xB	NULL
is	NULL
virtually	NULL
ubiquitous	NULL
(	NULL
Baeuerle	NULL
,	NULL
1991	NULL
)	NULL
and	NULL
therefore	NULL
some	NULL
of	NULL
the	NULL
mechanism-based	NULL
toxicities	NULL
associated	NULL
with	NULL
FK-506	NULL
and	NULL
CsA	NULL
might	NULL
result	NULL
from	NULL
inhibition	NULL
of	NULL
calcineurin-dependent	NULL
NF-xB	NULL
induction	NULL
.	NULL

Alternatively	NULL
,	NULL
a	NULL
kinase	NULL
activated	NULL
by	NULL
calcineurin	NULL
could	NULL
have	NULL
roles	NULL
in	NULL
non-T	NULL
cells	NULL
other	NULL
than	NULL
inactivation	NULL
of	NULL
IxB	NULL
.	NULL

Thus	NULL
further	NULL
analysis	NULL
868	NULL
determining	NULL
whether	NULL
calcineurin	NULL
can	NULL
induce	NULL
NF-xB	NULL
in	NULL
non-T	NULL
cells	NULL
and	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
calcineurin-activated	NULL
kinase	NULL
might	NULL
lead	NULL
to	NULL
a	NULL
better	NULL
understanding	NULL
of	NULL
the	NULL
toxicities	NULL
of	NULL
these	NULL
drugs	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Tissue	NULL
culture	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
passaged	NULL
and	NULL
transfected	NULL
,	NULL
and	NULL
reporter	NULL
genes	NULL
were	NULL
assayed	NULL
as	NULL
described	NULL
(	NULL
O'Keefe	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
grown	NULL
to	NULL
a	NULL
density	NULL
of	NULL
4-6	NULL
x	NULL
105/ml	NULL
.	NULL

Transfection	NULL
was	NULL
by	NULL
electroporation	NULL
(	NULL
10	NULL
'	NULL
cells	NULL
in	NULL
300	NULL
ul	NULL
of	NULL
RPMI	NULL
,	NULL
10	NULL
%	NULL
FCS	NULL
;	NULL
room	NULL
temperature	NULL
,	NULL
960	NULL
uF	NULL
,	NULL
250	NULL
V	NULL
,	NULL
0.4	NULL
cm	NULL
cuvette	NULL
,	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
)	NULL
.	NULL

Final	NULL
concentrations	NULL
of	NULL
inducers	NULL
(	NULL
except	NULL
where	NULL
noted	NULL
)	NULL
and	NULL
inhibitors	NULL
were	NULL
:	NULL
PMA	NULL
,	NULL
25	NULL
ng/ml	NULL
;	NULL
ionomycin	NULL
,	NULL
3.5	NULL
ug/ml	NULL
;	NULL
FK-506	NULL
,	NULL
10	NULL
ng/ml	NULL
.	NULL

Before	NULL
activation	NULL
or	NULL
drug	NULL
treatment	NULL
each	NULL
culture	NULL
of	NULL
transfected	NULL
cells	NULL
was	NULL
divided	NULL
into	NULL
the	NULL
appropriate	NULL
number	NULL
of	NULL
aliquots	NULL
.	NULL

After	NULL
treatment	NULL
(	NULL
12-16	NULL
h	NULL
)	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
lysed	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
(	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
and	NULL
B-galactosidase	NULL
(	NULL
Hollon	NULL
and	NULL
Yoshimura	NULL
,	NULL
1989	NULL
)	NULL
activities	NULL
.	NULL

Plasmid	NULL
constructs	NULL
The	NULL
test	NULL
promoters	NULL
are	NULL
in	NULL
either	NULL
pDAn.O0.CAT	NULL
or	NULL
pTAn.0.CAT	NULL
(	NULL
as	NULL
indicated	NULL
)	NULL
which	NULL
were	NULL
derived	NULL
from	NULL
pSV2cat	NULL
(	NULL
Gorman	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
by	NULL
deleting	NULL
the	NULL
NdeI	NULL
-	NULL
HindIII	NULL
fragment	NULL
(	NULL
containing	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
)	NULL
and	NULL
replacing	NULL
it	NULL
with	NULL
a	NULL
polylinker	NULL
(	NULL
Ndel	NULL
,	NULL
BgM	NULL
,	NULL
Smal	NULL
,	NULL
Clal	NULL
,	NULL
HindIII	NULL
)	NULL
and	NULL
then	NULL
inserting	NULL
two	NULL
(	NULL
D	NULL
)	NULL
or	NULL
three	NULL
(	NULL
T	NULL
)	NULL
tandem	NULL
copies	NULL
of	NULL
an	NULL
SV40	NULL
polyadenylation	NULL
sequence	NULL
,	NULL
bp	NULL
2532-2774	NULL
of	NULL
SV40	NULL
(	NULL
Tooze	NULL
,	NULL
1982	NULL
)	NULL
from	NULL
plasmid	NULL
p63-29	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
G.	NULL
Hollis	NULL
(	NULL
MRL	NULL
)	NULL
into	NULL
the	NULL
Bg/II	NULL
site	NULL
.	NULL

pDAn.yf.CAT	NULL
contains	NULL
a	NULL
gamma-fibrinogen	NULL
basal	NULL
element	NULL
(	NULL
Durand	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
inserted	NULL
between	NULL
the	NULL
polyadenylation	NULL
sequences	NULL
and	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

pTAn.A.4	NULL
and	NULL
pTAn.E.3	NULL
contain	NULL
the	NULL
synthetic	NULL
promoters	NULL
from	NULL
pA	NULL
4.1	NULL
and	NULL
pE	NULL
3.1	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
similarly	NULL
inserted	NULL
.	NULL

pTAn.xB.6	NULL
contains	NULL
a	NULL
promoter	NULL
consisting	NULL
of	NULL
six	NULL
copies	NULL
of	NULL
an	NULL
NF-xB	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
CMV-IE	NULL
promoter	NULL
(	NULL
CTAACGGGACTTTCCAA	NULL
)	NULL
derived	NULL
from	NULL
a	NULL
plasmid	NULL
provided	NULL
by	NULL
M.	NULL
Stinski	NULL
(	NULL
University	NULL
of	NULL
Iowa	NULL
,	NULL
Iowa	NULL
City	NULL
)	NULL
fused	NULL
to	NULL
the	NULL
y-fibrinogen	NULL
basal	NULL
element	NULL
and	NULL
inserted	NULL
as	NULL
the	NULL
others	NULL
.	NULL

pDAn.AP-1.3	NULL
contains	NULL
a	NULL
promoter	NULL
consisting	NULL
of	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
found	NULL
in	NULL
the	NULL
human	NULL
metallothionein	NULL
IIA	NULL
promoter	NULL
(	NULL
GTGACTCAGCGCG	NULL
)	NULL
(	NULL
Angel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
fused	NULL
to	NULL
the	NULL
same	NULL
basal	NULL
element	NULL
and	NULL
inserted	NULL
as	NULL
the	NULL
others	NULL
.	NULL

pTAn.IL	NULL
is	NULL
similar	NULL
to	NULL
p	NULL
(	NULL
An	NULL
)	NULL
IL2.CAT	NULL
(	NULL
O'Keefe	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
except	NULL
that	NULL
it	NULL
contains	NULL
a	NULL
series	NULL
of	NULL
three	NULL
SV40	NULL
polyadenylation	NULL
signals	NULL
rather	NULL
than	NULL
one	NULL
.	NULL

pCMV.Gal	NULL
and	NULL
peDL-SRa296	NULL
were	NULL
previously	NULL
described	NULL
(	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

pSRa4ACaM-Al	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
previously	NULL
described	NULL
pSRa-ACaM-AI	NULL
(	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
except	NULL
that	NULL
it	NULL
contains	NULL
an	NULL
additional	NULL
75	NULL
bp	NULL
of	NULL
5	NULL
'	NULL
untranslated	NULL
sequence	NULL
from	NULL
CNo4	NULL
(	NULL
Kincaid	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

pSRoCaNB	NULL
contains	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
regulatory	NULL
subunit	NULL
of	NULL
murine	NULL
calcineurin	NULL
(	NULL
Ueki	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
inserted	NULL
between	NULL
the	NULL
Psfl	NULL
and	NULL
KpnI	NULL
sites	NULL
of	NULL
peDL-SRo296	NULL
.	NULL

pSRaMAD3	NULL
contains	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
cDNA	NULL
MAD3	NULL
(	NULL
Haskill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
from	NULL
the	NULL
plasmid	NULL
pC3a/MAD3	NULL
inserted	NULL
between	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
the	NULL
expression	NULL
plasmid	NULL
peDL-SRa296	NULL
.	NULL

pSRaMAD3-hisg	NULL
is	NULL
identical	NULL
to	NULL
pSRaMAD3	NULL
except	NULL
that	NULL
it	NULL
has	NULL
six	NULL
histidine	NULL
codons	NULL
fused	NULL
to	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
MAD3	NULL
.	NULL

Extract	NULL
preparation	NULL
When	NULL
extracts	NULL
were	NULL
made	NULL
from	NULL
transfected	NULL
cells	NULL
each	NULL
was	NULL
generated	NULL
from	NULL
2	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
transfected	NULL
with	NULL
30	NULL
ug	NULL
of	NULL
DNA	NULL
.	NULL

16-18	NULL
h	NULL
after	NULL
transfection	NULL
cultures	NULL
were	NULL
treated	NULL
as	NULL
indicated	NULL
and	NULL
incubated	NULL
for	NULL
varying	NULL
lengths	NULL
of	NULL
time	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
300	NULL
al	NULL
of	NULL
buffer	NULL
A	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
(	NULL
in	NULL
a	NULL
1.5	NULL
ml	NULL
Eppendorf	NULL
tube	NULL
)	NULL
for	NULL
15	NULL
min	NULL
.	NULL

15	NULL
gl	NULL
of	NULL
10	NULL
%	NULL
NP-40	NULL
was	NULL
then	NULL
added	NULL
and	NULL
immediately	NULL
thereafter	NULL
the	NULL
nuclei	NULL
were	NULL
separated	NULL
from	NULL
the	NULL
cytosol	NULL
by	NULL
centrifugation	NULL
at	NULL
high	NULL
speed	NULL
in	NULL
an	NULL
Eppendorf	NULL
centrifuge	NULL
.	NULL

The	NULL
supernatant	NULL
,	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
cytosolic	NULL
fraction	NULL
,	NULL
was	NULL
removed	NULL
and	NULL
stabilized	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
60	NULL
gl	NULL
of	NULL
50	NULL
%	NULL
glycerol	NULL
.	NULL

The	NULL
nuclear	NULL
peliet	NULL
was	NULL
resuspended	NULL
in	NULL
100	NULL
41	NULL
of	NULL
buffer	NULL
C	NULL
by	NULL
vigorous	NULL
pipetting	NULL
and	NULL
then	NULL
gently	NULL
rocked	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
nuclei	NULL
were	NULL
removed	NULL
by	NULL
high	NULL
speed	NULL
centrifugation	NULL
for	NULL
5	NULL
min	NULL
in	NULL
an	NULL
Eppendorf	NULL
centrifuge	NULL
.	NULL

This	NULL
supernatant	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
nuclear	NULL
extract	NULL
.	NULL

Cytoplasmic	NULL
fraction	NULL
or	NULL
nuclear	NULL
extract	NULL
were	NULL
used	NULL
immediately	NULL
or	NULL
aliquoted	NULL
and	NULL
frozen	NULL
in	NULL
liquid	NULL
N	NULL
;	NULL
.	NULL

Buffer	NULL
A	NULL
contains	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
15	NULL
mM	NULL
KCl	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
2	NULL
ug/ml	NULL
leupeptin	NULL
and	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
.	NULL

Buffer	NULL
C	NULL
contains	NULL
25	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
400	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.1	NULL
%	NULL
NP-40	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
2	NULL
ug/ml	NULL
leupeptin	NULL
and	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
.	NULL

When	NULL
extracts	NULL
were	NULL
generated	NULL
from	NULL
non-transfected	NULL
cells	NULL
,	NULL
similar	NULL
cell	NULL
numbers	NULL
and	NULL
volumes	NULL
were	NULL
used	NULL
.	NULL

DNA	NULL
binding	NULL
assay	NULL
Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
20	NULL
al	NULL
volumes	NULL
consisting	NULL
of	NULL
12.5	NULL
mM	NULL
HEPES	NULL
pH	NULL
7.5	NULL
,	NULL
10	NULL
mM	NULL
Tris	NULL
pH	NULL
7.5	NULL
,	NULL
up	NULL
to	NULL
200	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.05	NULL
%	NULL
NP-40	NULL
,	NULL
12	NULL
%	NULL
glycerol	NULL
,	NULL
250	NULL
ug/ml	NULL
BSA	NULL
,	NULL
2	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
100	NULL
pg	NULL
of	NULL
end-labeled	NULL
double-stranded	NULL
oligonucleotide	NULL
.	NULL

To	NULL
visualize	NULL
NF-xB	NULL
DNA-protein	NULL
complexes	NULL
15	NULL
ug	NULL
of	NULL
cytosolic	NULL
fraction	NULL
or	NULL
8	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
used	NULL
;	NULL
to	NULL
visualize	NULL
Oct-1	NULL
DNA-protein	NULL
complexes	NULL
,	NULL
15	NULL
pg	NULL
of	NULL
cytosolic	NULL
fraction	NULL
or	NULL
4	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
used	NULL
.	NULL

Anti-p65	NULL
antibody	NULL
[	NULL
sc-109X	NULL
%	NULL
X	NULL
,	NULL
raised	NULL
against	NULL
an	NULL
amino-terminal	NULL
peptide	NULL
(	NULL
ELFPLIFPAEPAQASGP	NULL
)	NULL
]	NULL
and	NULL
the	NULL
anti-peptide	NULL
antibody	NULL
to	NULL
p50	NULL
(	NULL
p50	NULL
AX	NULL
,	NULL
NLS	NULL
raised	NULL
against	NULL
the	NULL
peptide	NULL
CYPEIKDKEEVQRKR	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
anti-p50	NULL
antiserum	NULL
was	NULL
raised	NULL
against	NULL
recombinant	NULL
KBF1	NULL
(	NULL
Kieran	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Protein	NULL
fractions	NULL
were	NULL
mixed	NULL
with	NULL
all	NULL
components	NULL
of	NULL
the	NULL
reaction	NULL
except	NULL
labeled	NULL
probe	NULL
,	NULL
which	NULL
was	NULL
added	NULL
last	NULL
.	NULL

When	NULL
extracts	NULL
were	NULL
treated	NULL
with	NULL
DOC	NULL
the	NULL
protein	NULL
component	NULL
of	NULL
a	NULL
reaction	NULL
was	NULL
brought	NULL
to	NULL
a	NULL
volume	NULL
of	NULL
10	NULL
pl	NULL
.	NULL

Sequentially	NULL
,	NULL
2	NULL
al	NULL
of	NULL
10	NULL
%	NULL
DOC	NULL
,	NULL
the	NULL
other	NULL
reaction	NULL
components	NULL
,	NULL
the	NULL
labeled	NULL
probe	NULL
and	NULL
2	NULL
al	NULL
of	NULL
10	NULL
%	NULL
NP-40	NULL
were	NULL
added	NULL
.	NULL

Reactions	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
and	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
(	NULL
Fried	NULL
and	NULL
Crothers	NULL
,	NULL
1981	NULL
;	NULL
Garner	NULL
and	NULL
Revzin	NULL
,	NULL
1981	NULL
)	NULL
on	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
x	NULL
TBE	NULL
(	NULL
Maniatis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
NF-xB	NULL
probe	NULL
was	NULL
5'-CTAGACTAACGGGACTITT-CCAAGAG-3	NULL
'	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
Oct	NULL
probe	NULL
was	NULL
5'-CTAGATATGCAA-ATCATTG-3	NULL
'	NULL
.	NULL

Probes	NULL
were	NULL
end-labeled	NULL
with	NULL
32P	NULL
by	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
using	NULL
standard	NULL
procedures	NULL
.	NULL

Images	NULL
of	NULL
the	NULL
dried	NULL
gel	NULL
and	NULL
quantitation	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
obtained	NULL
from	NULL
12-24	NULL
h	NULL
exposures	NULL
with	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Visualization	NULL
of	NULL
IxB	NULL
For	NULL
Western	NULL
blotting	NULL
of	NULL
whole	NULL
cell	NULL
lysates	NULL
4	NULL
x	NULL
106	NULL
Jurkat	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
cold	NULL
PBS	NULL
containing	NULL
1	NULL
mM	NULL
Na	NULL
;	NULL
VO	NULL
,	NULL
and	NULL
lysed	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
in	NULL
250	NULL
gl	NULL
of	NULL
a	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
50	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
10	NULL
pg/ml	NULL
pepstatin	NULL
and	NULL
1	NULL
mM	NULL
Na	NULL
;	NULL
VO4	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
using	NULL
standard	NULL
Bradford	NULL
Reagent	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

100	NULL
ug	NULL
of	NULL
protein	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
10	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
under	NULL
denaturing	NULL
and	NULL
reducing	NULL
conditions	NULL
,	NULL
transferred	NULL
to	NULL
PVDF	NULL
(	NULL
Millipore	NULL
)	NULL
membrane	NULL
,	NULL
immunoblotted	NULL
with	NULL
anti-MAD3	NULL
antiserum	NULL
,	NULL
and	NULL
visualized	NULL
by	NULL
the	NULL
ECL	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

For	NULL
immunoprecipitations	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
50	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
10	NULL
pg/ml	NULL
pepstatin	NULL
,	NULL
10	NULL
ug/ml	NULL
antipain	NULL
.	NULL

Antibody	NULL
-protein	NULL
complexes	NULL
were	NULL
precipitated	NULL
with	NULL
protein	NULL
G-agarose	NULL
beads	NULL
(	NULL
Gibco	NULL
)	NULL
by	NULL
standard	NULL
procedures	NULL
.	NULL

For	NULL
NiZ*t-agarose	NULL
(	NULL
Qiagen	NULL
,	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
precipitations	NULL
4	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
lysed	NULL
by	NULL
a	NULL
30	NULL
min	NULL
incubation	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
a	NULL
buffer	NULL
containing	NULL
6	NULL
M	NULL
guanidine-	NULL
HCl	NULL
,	NULL
100	NULL
mM	NULL
NaH	NULL
,	NULL
PO	NULL
,	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
.	NULL

Lysed	NULL
cells	NULL
were	NULL
sheared	NULL
with	NULL
a	NULL
20g	NULL
needle	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
100	NULL
L1	NULL
of	NULL
Niz*	NULL
-agarose	NULL
beads	NULL
.	NULL

Protein	NULL
was	NULL
eluted	NULL
in	NULL
500	NULL
gl	NULL
of	NULL
4	NULL
M	NULL
urea	NULL
,	NULL
50	NULL
mM	NULL
NaH	NULL
;	NULL
PO	NULL
,	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
500	NULL
mM	NULL
imidazole	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
.	NULL

The	NULL
eluted	NULL
protein	NULL
was	NULL
concentrated	NULL
to	NULL
50	NULL
ul	NULL
by	NULL
ultrafiltration	NULL
with	NULL
a	NULL
Millipore	NULL
Ultrafree/MC	NULL
(	NULL
10	NULL
000	NULL
nominal	NULL
mol	NULL
.	NULL

wt	NULL
cut-off	NULL
)	NULL
filtration	NULL
unit	NULL
.	NULL

Precipitated	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
under	NULL
denaturing	NULL
and	NULL
reducing	NULL
conditions	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
to	NULL
PVDF	NULL
membrane	NULL
and	NULL
immunoblotted	NULL
by	NULL
standard	NULL
methods	NULL
.	NULL

Anti-MAD3	NULL
antiserum	NULL
was	NULL
raised	NULL
against	NULL
bacterially	NULL
produced	NULL
recombinant	NULL
MAD3	NULL
.	NULL

CIP	NULL
treatment	NULL
of	NULL
precipitated	NULL
IxB/MAD3-hisg	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
bovine	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
Sigma	NULL
,	NULL
P5521	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
20	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
10	NULL
ug/ml	NULL
pepstatin	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
.	NULL

Phosphatase	NULL
inhibitors	NULL
used	NULL
were	NULL
1	NULL
mM	NULL
Na	NULL
;	NULL
VO	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
NaF	NULL
.	NULL

Acknowledgements	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
R.Boris	NULL
for	NULL
providing	NULL
FK-506	NULL
,	NULL
N.	NULL
Arai	NULL
(	NULL
DNAX	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
plasmid	NULL
,	NULL
pecDL-SRa29	NULL
%	NULL
6	NULL
,	NULL
G.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
providing	NULL
plasmids	NULL
pA4.1	NULL
and	NULL
pE3.1	NULL
,	NULL
J.Siekierka	NULL
for	NULL
providing	NULL
Jurkat	NULL
cells	NULL
,	NULL
A.Israél	NULL
(	NULL
Institute	NULL
Pasteur	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
for	NULL
providing	NULL
antibodies	NULL
to	NULL
p50	NULL
,	NULL
G.Engler	NULL
(	NULL
Chiron	NULL
Corp.	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
plasmid	NULL
pC3a	NULL
,	NULL
R.Hay	NULL
(	NULL
University	NULL
of	NULL
St	NULL
Andrews	NULL
,	NULL
St	NULL
Andrews	NULL
,	NULL
Fife	NULL
,	NULL
Scotland	NULL
)	NULL
for	NULL
providing	NULL
antibodies	NULL
to	NULL
MAD3	NULL
,	NULL
P.	NULL
Fischer	NULL
and	NULL
Dutch	NULL
Boltz	NULL
for	NULL
help	NULL
with	NULL
FACS	NULL
analysis	NULL
and	NULL
D.	NULL
Weinberg	NULL
,	NULL
A.	NULL
Williamson	NULL
and	NULL
R.Wobbe	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

Calcineurin	NULL
stimulates	NULL
inactivation	NULL
of	NULL
xB	NULL
References	NULL
Alford	NULL
,	NULL
R.H	NULL
.	NULL

(	NULL
1970	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
104	NULL
,	NULL
698-703	NULL
.	NULL

Altmeyer	NULL
,	NULL
A.	NULL
,	NULL
Staruch	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
Fischer	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
Durette	NULL
,	NULL
P.L	NULL
.	NULL

,	NULL
Tocci	NULL
,	NULL
M.J.	NULL
,	NULL
Sigal	NULL
,	NULL
N.H	NULL
.	NULL

and	NULL
Dumont	NULL
,	NULL
.F.J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Int	NULL
.	NULL

J	NULL
.	NULL

Immunopharmac	NULL
.	NULL

,	NULL
13	NULL
,	NULL
1187-1199	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.J.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
,	NULL
49	NULL
,	NULL
729-739	NULL
.	NULL

Bacuerie	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1072	NULL
,	NULL
63-80	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baitimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1988a	NULL
)	NULL
Cell	NULL
,	NULL
53	NULL
,	NULL
211-217	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baitimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1988b	NULL
)	NULL
Science	NULL
,	NULL
242	NULL
,	NULL
540-546	NULL
.	NULL

Baumann	NULL
,	NULL
G.	NULL
,	NULL
Geisse	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Sullivan	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
New	NULL
Bio/	NULL
.	NULL

,	NULL
3	NULL
,	NULL
270-278	NULL
.	NULL

Beg	NULL
,	NULL
A.A.	NULL
,	NULL
Ruben	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
Scheinman	NULL
,	NULL
R.I.	NULL
,	NULL
Haskill	NULL
,	NULL
S.	NULL
,	NULL
Rosen	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Baldwin	NULL
,	NULL
A.S.	NULL
(	NULL
1992	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
6	NULL
,	NULL
1899-1913	NULL
.	NULL

Beg	NULL
,	NULL
A.A.	NULL
,	NULL
Finco	NULL
,	NULL
T.	NULL
$	NULL
.	NULL

,	NULL
Nantermet	NULL
,	NULL
P.V	NULL
.	NULL

and	NULL
Baldwin	NULL
,	NULL
A.S.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
3301-3310	NULL
.	NULL

Berridge	NULL
,	NULL
M.J.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
,	NULL
361	NULL
,	NULL
315-325	NULL
.	NULL

Blank	NULL
,	NULL
V.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
17	NULL
,	NULL
135-140	NULL
.	NULL

Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Pictrowski	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Serfling	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
19	NULL
,	NULL
61-67	NULL
.	NULL

Briegel.K	NULL
.	NULL

,	NULL
Hentsch	NULL
,	NULL
B.	NULL
,	NULL
Pfeuffer.I	NULL
.	NULL

and	NULL
Serfling	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
19	NULL
,	NULL
5929-5936	NULL
.	NULL

Brown	NULL
,	NULL
K.	NULL
,	NULL
Park	NULL
,	NULL
S.	NULL
,	NULL
Kanno	NULL
,	NULL
T.	NULL
,	NULL
Franzoso	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Sicbenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
2532-2536	NULL
.	NULL

Clipstone	NULL
,	NULL
N.A	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
,	NULL
357	NULL
,	NULL
695-697	NULL
.	NULL

Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
243	NULL
,	NULL
355-361	NULL
.	NULL

Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Bush	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
Replogle	NULL
,	NULL
Belagaje	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
1715-1724	NULL
.	NULL

Emmel	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
Verweij	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Higgins	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Lacy	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
246	NULL
,	NULL
1617-1620	NULL
.	NULL

Fan	NULL
,	NULL
C.-M.	NULL
and	NULL
Maniatis	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
,	NULL
354	NULL
,	NULL
395-398	NULL
.	NULL

Flanagan	NULL
,	NULL
M	NULL
.	NULL

W.	NULL
,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.J	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
,	NULL
352	NULL
,	NULL
803-807	NULL
.	NULL

Fried	NULL
,	NULL
M.	NULL
and	NULL
Crothers	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1981	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
9	NULL
,	NULL
6505-6525	NULL
.	NULL

Fruman	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Klee	NULL
,	NULL
C.B	NULL
.	NULL

,	NULL
Bierer	NULL
,	NULL
B.E	NULL
.	NULL

and	NULL
Burakoff	NULL
,	NULL
S.J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
3686-3690	NULL
.	NULL

Garner	NULL
,	NULL
and	NULL
Revzin	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
9	NULL
,	NULL
3047-3060	NULL
.	NULL

Ghosh	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
,	NULL
344	NULL
,	NULL
678-682	NULL
.	NULL

Gorman	NULL
,	NULL
C	NULL
.	NULL

M.	NULL
,	NULL
Moffat	NULL
,	NULL
L.F	NULL
.	NULL

and	NULL
Howard	NULL
,	NULL
B.H	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
1044-1051	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
Andrus	NULL
,	NULL
L.	NULL
and	NULL
Steinman	NULL
,	NULL
R.M	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
163	NULL
,	NULL
922-937	NULL
.	NULL

Gunter	NULL
,	NULL
Irving	NULL
,	NULL
$	NULL
.G	NULL
.	NULL

,	NULL
Zipfel	NULL
,	NULL
P.F	NULL
.	NULL

,	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

and	NULL
Kelly	NULL
,	NULL
K	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
142	NULL
,	NULL
3286-3291	NULL
.	NULL

Haskill	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Beg	NULL
,	NULL
A.A.	NULL
,	NULL
Tompkins	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
Morris	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Yurochko	NULL
,	NULL
A.D.	NULL
,	NULL
Sampson-Johannes	NULL
,	NULL
A.	NULL
,	NULL
Mondal	NULL
,	NULL
K.	NULL
,	NULL
Ralph	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Baldwin	NULL
,	NULL
A.S.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
,	NULL
65	NULL
,	NULL
1281-1289	NULL
.	NULL

Hollon	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Yoshimura	NULL
,	NULL
F.K	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
182	NULL
,	NULL
411-418	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
Ballard	NULL
,	NULL
D.W.	NULL
,	NULL
Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Siekevitz	NULL
,	NULL
.M	NULL
.	NULL

and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
244	NULL
,	NULL
457-460	NULL
.	NULL

-I.	NULL
,	NULL
Kerr	NULL
,	NULL
L.D	NULL
.	NULL

,	NULL
Rashid	NULL
,	NULL
D.	NULL
,	NULL
Davis	NULL
,	NULL
N.	NULL
,	NULL
Bose	NULL
,	NULL
H.R	NULL
.	NULL

and	NULL
Verma	NULL
,	NULL
L	NULL
.	NULL

M.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
4333-4337	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.E	NULL
.	NULL

and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992a	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
148	NULL
,	NULL
1240-1250	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.G	NULL
.	NULL

,	NULL
Valge-Archer	NULL
,	NULL
V.E	NULL
.	NULL

and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992b	NULL
)	NULL
Nature	NULL
,	NULL
356	NULL
,	NULL
801-804	NULL
.	NULL

Kamps	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
Corcoran	NULL
,	NULL
L.	NULL
,	NULL
LeBowitz	NULL
,	NULL
J.H	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
5464-5472	NULL
.	NULL

Kerr	NULL
,	NULL
L.D	NULL
.	NULL

,	NULL
Inoue	NULL
,	NULL
J.-i	NULL
.	NULL

,	NULL
Davis	NULL
,	NULL
N.	NULL
,	NULL
Link	NULL
,	NULL
E.	NULL
,	NULL
Baeuerle	NULL
,	NULL
P	NULL
.	NULL

A.	NULL
,	NULL
Bose	NULL
,	NULL
H.R	NULL
.	NULL

and	NULL
Verma	NULL
,	NULL
I.M	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
5	NULL
,	NULL
1464-1476	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Vandekerckhove	NULL
,	NULL
J.	NULL
,	NULL
Lottspeich	NULL
,	NULL
F.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Urban	NULL
,	NULL
M.B	NULL
.	NULL

,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Bacuerle	NULL
,	NULL
P	NULL
.	NULL

A.	NULL
and	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
1007-1018	NULL
.	NULL

Kincaid	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
Takayama	NULL
,	NULL
H.	NULL
,	NULL
Billingsley	NULL
,	NULL
M.L	NULL
.	NULL

and	NULL
Sitkovsky	NULL
,	NULL
M.V	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
330	NULL
,	NULL
176-178	NULL
.	NULL

Kincaid	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
Giri	NULL
,	NULL
P.R	NULL
.	NULL

,	NULL
Higuchi	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Dixon	NULL
,	NULL
$	NULL
S.C.	NULL
,	NULL
Marietta	NULL
,	NULL
C	NULL
.	NULL

A.	NULL
,	NULL
Amorese	NULL
,	NULL
D.	NULL
A.	NULL
and	NULL
Martin	NULL
,	NULL
B.M	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
,	NULL
265	NULL
,	NULL
11312-11319	NULL
.	NULL

Kronke	NULL
,	NULL
M.	NULL
,	NULL
Leonard	NULL
,	NULL
W.J	NULL
.	NULL

,	NULL
Depper	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Arya	NULL
,	NULL
S.K	NULL
.	NULL

,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
Gallo	NULL
,	NULL
R.C	NULL
.	NULL

,	NULL
Waldman	NULL
,	NULL
T	NULL
.	NULL

A.	NULL
and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
81	NULL
,	NULL
5214-5218	NULL
.	NULL

Lee	NULL
,	NULL
W.	NULL
,	NULL
Mitchell	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
,	NULL
49	NULL
,	NULL
741-752	NULL
.	NULL

Link	NULL
,	NULL
E.	NULL
,	NULL
Kerr	NULL
,	NULL
L.D	NULL
.	NULL

,	NULL
Schreck	NULL
,	NULL
R.	NULL
,	NULL
Zabel	NULL
,	NULL
U.	NULL
,	NULL
Verma	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
267	NULL
,	NULL
239-246	NULL
.	NULL

Liv	NULL
,	NULL
J.	NULL
,	NULL
Farmer	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Lane	NULL
,	NULL
Friedman	NULL
,	NULL
J.	NULL
,	NULL
Wiessman	NULL
,	NULL
L	NULL
and	NULL
Schreiber	NULL
,	NULL
S.L	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
,	NULL
66	NULL
,	NULL
807-815	NULL
.	NULL

869	NULL
B.Frantz	NULL
et	NULL
al	NULL
.	NULL

Liu	NULL
,	NULL
J.	NULL
,	NULL
Albers	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Wandless	NULL
,	NULL
T.J.	NULL
,	NULL
Luan	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Alberg	NULL
,	NULL
D.G	NULL
.	NULL

,	NULL
Belshaw	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
Cohen	NULL
,	NULL
P.	NULL
,	NULL
MacKintosh	NULL
,	NULL
C.	NULL
,	NULL
Klee	NULL
,	NULL
C.B	NULL
.	NULL

and	NULL
Schreiber	NULL
,	NULL
S.L	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Biochemistry	NULL
,	NULL
31	NULL
,	NULL
3896-3901	NULL
.	NULL

Manger	NULL
,	NULL
B.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
Weyand	NULL
,	NULL
C.	NULL
,	NULL
Goronzy	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Stobo	NULL
,	NULL
J.D	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

,	NULL
135	NULL
,	NULL
3669-3673	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.F	NULL
.	NULL

and	NULL
Sambrook	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Molecular	NULL
Cloning	NULL
.	NULL

A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

Mattila	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Fiering	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Emmel	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
McCutcheon	NULL
,	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Herzenberg	NULL
,	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
4425-4433	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
DiDonato.J	NULL
.	NULL

A.	NULL
,	NULL
Rosette	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
705-718	NULL
.	NULL

Minshull	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
BioEssays	NULL
,	NULL
15	NULL
,	NULL
149-155	NULL
.	NULL

Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Mattila	NULL
,	NULL
P.S	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
175	NULL
,	NULL
1235-1245	NULL
.	NULL

O'Keefe	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
Tocci	NULL
,	NULL
M.J	NULL
.	NULL

and	NULL
O'Neill	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
,	NULL
357	NULL
,	NULL
692-694	NULL
.	NULL

Randak	NULL
,	NULL
C.	NULL
,	NULL
Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Hergenrother	NULL
,	NULL
M.	NULL
,	NULL
Sobotta	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Serfling	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
2529-2536	NULL
.	NULL

Riegel	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Flanagan	NULL
,	NULL
W.M	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
In	NULL
Kishimoto	NULL
,	NULL
T	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Interleukins	NULL
:	NULL
Molecular	NULL
Biology	NULL
and	NULL
Immunology	NULL
.	NULL

Karger	NULL
,	NULL
Basel	NULL
,	NULL
Vol	NULL
.	NULL

51	NULL
,	NULL
266-298	NULL
.	NULL

Schmid	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
Perkins	NULL
,	NULL
Duckett	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
Andrews	NULL
,	NULL
P.C	NULL
.	NULL

and	NULL
Nabel	NULL
,	NULL
G.J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
,	NULL
352	NULL
,	NULL
733-736	NULL
.	NULL

Schmidt	NULL
,	NULL
A.	NULL
,	NULL
Hennighausen	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
,	NULL
4037-4041	NULL
.	NULL

Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Yoneyama	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Taniguchi	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
1	NULL
,	NULL
43-49	NULL
.	NULL

Shirakawa	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Mizel	NULL
,	NULL
$	NULL
.B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
2424-2430	NULL
.	NULL

Sigal	NULL
,	NULL
and	NULL
Dumont	NULL
,	NULL
F.J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
519-560	NULL
.	NULL

Sun	NULL
,	NULL
$	NULL
.-C.	NULL
,	NULL
Ganchi	NULL
,	NULL
P	NULL
.	NULL

A.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
,	NULL
259	NULL
,	NULL
1912-1915	NULL
.	NULL

Thompson	NULL
,	NULL
C.B	NULL
.	NULL

,	NULL
Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
Ho	NULL
,	NULL
I.-C.	NULL
,	NULL
Bohjanen	NULL
,	NULL
P.R	NULL
.	NULL

,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Miesfeldt	NULL
,	NULL
S.	NULL
,	NULL
Zhang	NULL
,	NULL
L.	NULL
,	NULL
Nabel	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
Karpinski	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Leiden	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
1043-1053	NULL
.	NULL

Tocci	NULL
,	NULL
M.J.	NULL
,	NULL
Matkovich	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Collier	NULL
,	NULL
K.A	NULL
.	NULL

,	NULL
Kwok	NULL
,	NULL
P.	NULL
,	NULL
Dumont	NULL
,	NULL
F.	NULL
,	NULL
Lin	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
DeGudicibus	NULL
,	NULL
S.	NULL
,	NULL
Siekierka	NULL
,	NULL
J.J.	NULL
,	NULL
Chin	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Hutchinson	NULL
,	NULL
N.I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
143	NULL
,	NULL
718-726	NULL
.	NULL

Todd	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Grusby	NULL
,	NULL
M.J.	NULL
,	NULL
Lederer	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
Lichtman	NULL
,	NULL
A.H	NULL
.	NULL

and	NULL
Glimcher	NULL
,	NULL
L.H	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
177	NULL
,	NULL
1663-1674	NULL
.	NULL

Truneh	NULL
,	NULL
A.	NULL
,	NULL
Albert	NULL
,	NULL
F.	NULL
,	NULL
Golstein	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Schmitt-Verhulst	NULL
,	NULL
A.-M.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
,	NULL
313	NULL
,	NULL
318-320	NULL
.	NULL

Ueki	NULL
,	NULL
K.	NULL
,	NULL
Muramatsu	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Kincaid	NULL
,	NULL
R.L	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
187	NULL
,	NULL
537-543	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Flanagan	NULL
,	NULL
W.M	NULL
.	NULL

,	NULL
Edwards	NULL
,	NULL
C	NULL
.	NULL

A.	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
,	NULL
254	NULL
,	NULL
558-562	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Admon	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
188-196	NULL
.	NULL

Received	NULL
on	NULL
September	NULL
3	NULL
,	NULL
1993	NULL
;	NULL
revised	NULL
on	NULL
November	NULL
24	NULL
,	NULL
1993	NULL
870	NULL

